Oncología Traslacional (ONCO-INVES)

Caraballo IG, Delgado BL, Zamorano MR, Salgado M, Pachon V, Galan JM,Castellon V, Gardeazabal I, Ferrer A, Perez JR, Escobar IG, Fernandez I,Quintanar T, Font C, Alsar JS, Moran LO, Fernandez JMS, Martin AJM. Comparativeanalysis of risk prediction scores including all types of cancer-associatedthrombosis. Clin Transl Oncol. 2026 Apr;28(4):1444-1450. doi:10.1007/s12094-025-04099-2. Epub 2025 Oct 26. PubMed PMID: 41139366.

Martin M, Guerrero-Zotano AL, Perez-Lopez ME, Ruiz-Borrego M, Martinez JanezN, Chacon JI, Gil-Gil M, Andres R, Bermejo B, Sanchez-Rovira P, Del Barco S,Ponce JJ, Fernandez I, Martinez de Duenas E, Hinojo-Gonzalez C, Gonzalez M,Garcia-Garre E, Hernando B, de la Haba-Rodriguez J, Alvarez IM, Gonzalez-SantiagoS, Garcia-Saenz JA, Santaballa A, Casas M, Bezares S, Caballero R, Rojo F, AlbaE. Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients withHR+/HER2- Highly Proliferative Breast Cancer. Clin Cancer Res. 2026 Mar2;32(5):850-858. doi: 10.1158/1078-0432.CCR-25-2435. PubMed PMID: 41385615;PubMed Central PMCID: PMC13056312.

Munera-Maravilla E, Perez-Escavy M, Rubio C, Segovia C, Lodewijk I, Nunes SP,Martin de Bernardo A, A Reina I, Montesinos E, Morales L, Martinez VG,Alvarez-Prada A, Martinez-Fernandez M, Duenas M, Paramio JM, Suarez-Cabrera C.Cell-of-origin and genetic drivers define advanced bladder cancer subtypes andpotential therapeutic response in mouse models. J Exp Clin Cancer Res. 2026 Feb23;45(1):79. doi: 10.1186/s13046-026-03677-8. PubMed PMID: 41724981; PubMedCentral PMCID: PMC13032214.

Zumalave S, Santamarina M, P Espasandin N, Zamora J, Garcia-Souto D, Temes J,Baker TM, Rodriguez-Castro J, Otero P, Pequeno-Valtierra A, Otero I, Oitaben A,Alvarez EG, Diaz-Arias I, Martinez-Fernandez M, Blanco MG, Van Loo P, CristofariG, Rodriguez-Martin B, Tubio JMC. Concurrent L1 retrotransposition events promotereciprocal translocations in human tumorigenesis. Science. 2026 Apr2;392(6793):eaee4513. doi: 10.1126/science.aee4513. Epub 2026 Apr 2. PubMed PMID:41747018.

Brea-Iglesias J, Gallardo-Gomez M, Oitaben A, Lazaro-Quintela ME, Leon L,Alves JM, Pino-Gonzalez M, Juaneda-Magdalena L, Garcia-Benito C, Abdulkader I,Muinelo L, Paramio JM, Martinez-Fernandez M. Genomics guiding personalizedfirst-line immunotherapy response in lung and bladder tumors. J Transl Med. 2025Apr 5;23(1):404. doi: 10.1186/s12967-025-06323-7. PubMed PMID: 40188131; PubMedCentral PMCID: PMC11972471.

Brea-Iglesias J, Oitaben A, Zumalave S, Rodriguez-Martin B, Gallardo-Gomez M,Santamarina M, Pequeno-Valtierra A, Juaneda-Magdalena L, Garcia-Escudero R,Lopez-Cedrun JL, Fraga M, Tubio JMC, Martinez-Fernandez M. Unraveling LINE-1retrotransposition in head and neck squamous cell carcinoma. Mol Oncol. 2025Dec;19(12):3769-3783. doi: 10.1002/1878-0261.70063. Epub 2025 Jun 4. PubMed PMID:40465458; PubMed Central PMCID: PMC12688165.

Cousillas Castineiras A, Gallardo Martin E, Fernandez Montes A, Carmona CamposM, Covela Rua M, Salgado Fernandez M, Pellon Augusto ML, Mendez Mendez JC, BrozosVazquez E, Martinez Lago N. Vitamin D-regulated miRNA expression in tumoral andnormal adjacent tissue of localized gastric cancer patients: the impact onsurvival and time to relapse. Transl Cancer Res. 2025 Jun 30;14(6):3702-3713.doi: 10.21037/tcr-24-2068. Epub 2025 Jun 27. PubMed PMID: 40687227; PubMedCentral PMCID: PMC12268756.

Fernandez Calvo O, Munoz Iglesias J, Abou Jokh Casas E, Molina-Diaz A, AnidoHerranz U, Casas Nebra J, Garcia-Bernardo L, Martinez-Breijo S, Lazaro-QuintelaM, Muniz-Garcia G, Vazquez-Estevez S. Recommendations from the GalicianOncological Society and the Galician Society of Nuclear Medicine for the use of177Lu-PSMA-617 radioligand-therapy in prostate cancer. Clin TranslOncol. 2025 Apr;27(4):1383-1397. doi: 10.1007/s12094-024-03662-7. Epub 2024 Sep12. PubMed PMID: 39266875; PubMed Central PMCID: PMC12000182.

Gallardo-Gomez M. Analysis of the Pattern of RNA Expression in the Skin ofTR-Deficient Mice By RNA-seq. Methods Mol Biol. 2025;2876:151-162. doi:10.1007/978-1-0716-4252-8_10. PubMed PMID: 39579314.

Iglesias-Perez C, Jimenez-Fonseca P, Lopez Robles J, Garcia Adrian S,Fernandez Perez I, Martinez Del Prado P, Rubio Perez J, Martinez de Castro E,Diaz Pedroche C, Garcia de Herreros M, Carmona Campos M, Ruperez Blanco AB,Salgado Fernandez M, Quintanar Verduguez T, Marrupe Gonzalez D, Covela Rua M,Santiago Crespo JA, Nieva Munoz M, Munoz A, Carmona-Bayonas A. Venous thrombosisin lung cancer compared with other tumors: results from the TESEO-SEOM registry.Thromb Res. 2025 Dec;256:109525. doi: 10.1016/j.thromres.2025.109525. Epub 2025Nov 3. PubMed PMID: 41237754.

Munoz Martin AJ, Castet F, Soto Alsar J, Adeva J, Peinado P, Grana B, AlesDiaz I, Rodriguez-Alonso RM, Lobo de Mena M, Vera R, Ruiz de Mena I, Aguilar S,Vega S, Ortega Moran L, Macarulla T. MDM2 amplification in a real-worldcohort of patients with biliary tract cancer from the Spanish RETUDgastrointestinal registry. ESMO Gastrointest Oncol. 2025 May 27;8:100187. doi:10.1016/j.esmogo.2025.100187. eCollection 2025 Jun. PubMed PMID: 41646279; PubMedCentral PMCID: PMC12836494.

Pino-Gonzalez M, Lazaro-Quintela M, Alonso-Alvarez I, Gallardo-Gomez M,Juaneda-Magdalena L, Francisco-Fernandez A, Calabuig-Farinas S, Jantus-LewintreE, Martinez-Fernandez M. Tissue and peripheral T cell receptor repertoirepredicts immunotherapy response and progression-free survival in NSCLC patients.Sci Rep. 2025 Nov 20;15(1):40914. doi: 10.1038/s41598-025-21612-3. PubMed PMID:41266384; PubMed Central PMCID: PMC12635383.

Salgado M, de la Camara-Gomez J, Garcia-Escobar I, Alvarez-Llosa RC,Gonzalez-Villarroel P, Garay DF, Pampols-Felip M, Guillot-Morales M,Pelegrin-Mateo FJ, Jimenez-Orozco E, Sastre J, de Castro EM, Coma E, Bouzas LP,Ferrer-Perez AI, Momprade-Olive E, Cousillas-Castineiras A, Covela-Rua M, RojasM, Querol R, Diaz LR, Merino M, Gil M, Sanchez-Canovas M, Elias T,Marrupe-Gonzalez D, Sanchez-Gil B, Carmona-Campos M, Garcia-Ferron M, Soria JM,Munoz A. Tinzaparin for the prevention of thromboembolic events in ambulatorypatients with metastatic colorectal cancer receiving first line treatment: arandomised, clinical trial design. BMC Cancer. 2025 Nov 17;25(1):1773. doi:10.1186/s12885-025-14620-z. PubMed PMID: 41249955; PubMed Central PMCID:PMC12621363.

Staehler M, Basso U, Eymard JC, Barthelemy P, Bigot P, Laramas M, Rink M,Suarez C, Guillot A, Bedke J, Hamberg P, De Vivo R, Gajate P, Lazaro-Quintela M,Rastogi P, Perrot V, Qvick B, Dutailly P, Verzoni E, Procopio G. A ProspectiveNon-interventional Real-World Study of cabozantinib in Pretreated Patients WithAdvanced Renal Cell Carcinoma Refractory to Vascular Endothelial GrowthFactor-Targeted Therapy (CASSIOPE). Clin Genitourin Cancer. 2025Feb;23(1):102285. doi: 10.1016/j.clgc.2024.102285. Epub 2024 Nov 30. PubMed PMID:39740313.

Varela M, Teixido C, Alvarez-Fernandez C, Arasanz H, Peralta S, Lazaro M,Calvo V, Alvarez R, Baena J, Valdivia J, Arriola E, Bernabe R, Isla D, Camacho C,Massuti B, Blasco A, Garcia T, Cobo M, Campayo M, Hijazo-Pechero S, Callejo A,Dominguez M, Nadal E. Prevalence of EGFR gene mutations in patients withearly-stage resectable non-small cell lung cancer in Spain: the ORIGEN study.Transl Lung Cancer Res. 2025 Apr 30;14(4):1254-1265. doi:10.21037/tlcr-2024-1146. Epub 2025 Apr 21. PubMed PMID: 40386732; PubMed CentralPMCID: PMC12082214.

Anido-Herranz U, Fernandez-Calvo O, Ruiz-Banobre J, Martinez-Breijo S,Fernandez-Nunez N, Nogareda-Seoane Z, Garrido-Pumar M, Casas-Nebra J,Muniz-Garcia G, Portela-Pereira P, Gomez-Caamano A, Perez-Fentes DA,Santome-Couto L, Lazaro M, Molina-Diaz A, Medina-Colmenero A, Vazquez-Estevez S.Outcomes and patterns of use of Radium-223 in metastatic castration-resistantprostate cancer. Front Oncol. 2024 May 7;14:1385466. doi:10.3389/fonc.2024.1385466. eCollection 2024. PubMed PMID: 38774416; PubMedCentral PMCID: PMC11106362.

Balmana J, Fasching PA, Couch FJ, Delaloge S, Labidi-Galy I, O’Shaughnessy J,Park YH, Eisen AF, You B, Bourgeois H, Goncalves A, Kemp Z, Swampillai A,Jankowski T, Sohn JH, Poddubskaya E, Mukhametshina G, Aksoy S, Timcheva CV,Park-Simon TW, Anton-Torres A, John E, Baria K, Gibson I, Gelmon KA; LUCYinvestigators [Isabel Lorenzo Lorenzo]. Clinical effectiveness and safety of olaparib in BRCA-mutated,HER2-negative metastatic breast cancer in a real-world setting: final analysis ofLUCY. Breast Cancer Res Treat. 2024 Apr;204(2):237-248. doi:10.1007/s10549-023-07165-x. Epub 2023 Dec 19. PubMed PMID: 38112922; PubMedCentral PMCID: PMC10948524.

Contreras-Toledo D, Jimenez-Fonseca P, Lopez CL, Montes AF, Lopez Munoz AM,Vazquez Rivera F, Alonso V, Alcaide J, Salva F, Covela Rua M, Guillot M, MartinCarnicero A, Jimeno Mate R, Cameselle Garcia S, Asensio Martinez E, GonzalezAstorga B, Fernandez-Diaz AB, Gonzalez Villaroel P, Virgili Manrique AC, MelianSosa M, Alonso B, Cousillas Castineiras A, Castanon Lopez C, Aparicio J,Carmona-Bayonas A. Dynamic nature of BRAF or KRAS p.G12C mutations in second-linetherapy for advanced colorectal cancer patients: do early and late effects exist?Br J Cancer. 2024 Mar;130(5):777-787. doi: 10.1038/s41416-023-02563-w. Epub 2024Jan 8. PubMed PMID: 38191609; PubMed Central PMCID: PMC10912758.

Gallardo-Gomez M, Costas-Rios L, Garcia-Prieto CA, Alvarez-Rodriguez L,Bujanda L, Barrero M, Castells A, Balaguer F, Jover R, Esteller M, Tardio BaigesA, Gonzalez-Carrero Fojon J, Cubiella J, De Chiara L. Serum DNA methylome of thecolorectal cancer serrated pathway enables non-invasive detection. Mol Oncol.2024 Nov;18(11):2696-2713. doi: 10.1002/1878-0261.13573. Epub 2024 Jan 10. PubMedPMID: 38129291; PubMed Central PMCID: PMC11547225.

Peressini M, Garcia-Campelo R, Massuti B, Marti C, Cobo M, Gutierrez V, DomineM, Fuentes J, Majem M, de Castro J, Cordoba JF, Diz MP, Isla D, Esteban E,Carcereny E, Vila L, Moreno-Vega A, Ros S, Moreno A, Garcia FJ, Huidobro G,Aguado C, Cebey-Lopez V, Valdivia J, Palmero R, Lianes P, Lopez-Brea M, Vidal OJ,Provencio M, Arriola E, Baena J, Herrera M, Bote H, Molero M, Adradas V,Ponce-Aix S, Nunez-Buiza A, Ucero A, Hernandez S, Lopez-Rios F, Conde E, Paz-AresL, Zugazagoitia J. Spatially Preserved Multi-Region Transcriptomic Subtyping andBiomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell LungCancer. Clin Cancer Res. 2024 Jul 15;30(14):3036-3049. doi:10.1158/1078-0432.CCR-24-0104. PubMed PMID: 38630755.

Salgado Fernandez M, Reboredo Lopez M, Covela Rua M, Candamio S,Gonzalez-Villarroel P, Sanchez-Cousido LF, Grana B, Carral-Maseda A,Cameselle-Garcia S, Varela Pose V, Gallardo-Martin ME, Martinez-Lago N; GalicianGroup of Research in Digestive Tumors (GITuD). Rechallenge with Anti-EGFRTreatment in RAS/BRAF wt Metastatic Colorectal Cancer (mCRC) in Real ClinicalPractice: Experience of the GITuD Group. Target Oncol. 2024 Jul;19(4):565-573.doi: 10.1007/s11523-024-01062-z. Epub 2024 May 23. PubMed PMID: 38780742.

Tokito T, Kolesnik O, Sorensen J, Artac M, Quintela ML, Lee JS, Hussein M,Pless M, Paz-Ares L, Leopold L, Daniel J, Munteanu M, Samkari A, Xu L, Butts C.Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-linetreatment for metastatic non-small cell lung cancer with high levels ofprogrammed death-ligand 1: a randomized, double-blind phase 2 study. BMC Cancer.2024 Jul 25;23(Suppl 1):1251. doi: 10.1186/s12885-023-11203-8. PubMed PMID:39054476; PubMed Central PMCID: PMC11270761.

Vaz-Salgado MA, Garcia BC, Perez IF, Munarriz BJ, Domarco PS, Gonzalez AH,Villar MV, Caro RL, Delgado MLV, Sanchez JMS. SEOM-GEINO clinical guidelines forgrade 2 gliomas (2023). Clin Transl Oncol. 2024 Nov;26(11):2856-2865. doi:10.1007/s12094-024-03456-x. Epub 2024 Apr 25. PubMed PMID: 38662171; PubMedCentral PMCID: PMC11467015.

Gallardo, M. Tyroid Hormones: Methods and Protocols. Analysis of the Pattern of RNA Expression in the Skin of TR-Deficient Mice By RNA-seq. Methods in Molecular Biology, vol. 2876. Springer Nature (2024). pp. 151-162
Enlace

Isabel Lorenzo Lorenzo. Ana Alonso Herrero. Isaura Fernandez Pérez. Capítulo 11: Factores Hormonales. EN: Manual SEOM de Prevención y Diagnóstico Precoz del Cáncer. 2ª Edición. 87-94. SOCIEDAD ESPAÑOLA DE ONCOLOGIA MEDICA (SEOM) 2024; ISBN 978-84-09-65861-9
Enlace

Aparicio I, Iranzo P, Reyes R, Bote H, Saigi M, Bringas M, Bosch-Barrera J,Corral J, Aparisi F, Ruffinelli JC, Jimenez B, Lage Y, Lopez-Castro R, Majem M,Vazquez S, Artal A, Rodriguez-Perez A, Lazaro-Quintela M, Torres JMS, Reguart N,Cucurull M, Gil-Bazo I, Camps C, Nadal E, Del Barrio A, Garrido P, Domine M,Alvarez R, Munoz AJ, Calles A. Brief report: High incidence of peridiagnosisthromboembolic events in patients with BRAF-mutant lung cancer. Thromb Res. 2023Dec;232:133-137. doi: 10.1016/j.thromres.2023.11.007. Epub 2023 Nov 12. PubMedPMID: 37976733.

Cueva JF, Palacio I, Churruca C, Herrero A, Pardo B, Constenla M, SantaballaA, Manso L, Estevez P, Maximiano C, Legeren M, Marquina G, de Juan A, Quindos M,Sanchez L, Barquin A, Fernandez I, Martin C, Juarez A, Martin T, Garcia Y, YuberoA, Gallego A, Martinez Bueno A, Guerra E, Gonzalez-Martin A. Real-world safetyand effectiveness of maintenance niraparib for platinum-sensitive recurrentovarian cancer: A GEICO retrospective observational study within the Spanishexpanded-access programme. Eur J Cancer. 2023 Mar;182:3-14. doi:10.1016/j.ejca.2022.12.023. Epub 2022 Dec 29. PubMed PMID: 36706655.

Gallardo-Gomez M, Rodriguez-Girondo M, Planell N, Moran S, Bujanda L, EtxartA, Castells A, Balaguer F, Jover R, Esteller M, Cubiella J, Gomez-Cabrero D, DeChiara L. Serum methylation of GALNT9, UPF3A, WARS, and LDB2 as noninvasivebiomarkers for the early detection of colorectal cancer and advanced adenomas.Clin Epigenetics. 2023 Oct 4;15(1):157. doi: 10.1186/s13148-023-01570-1. PubMedPMID: 37794510; PubMed Central PMCID: PMC10552320.

Isla D, Sanchez A, Casal J, Cobo M, Majem M, Reguart N, Zugazagoitia J,Bernabe R. PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment ofAdvanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: AnExpert Position Statement. J Clin Med. 2023 Aug 1;12(15):5063. doi:10.3390/jcm12155063. PubMed PMID: 37568465; PubMed Central PMCID: PMC10420126.

Martin-Sanchez F, Lazaro M, Lopez-Otin C, Andreu AL, Cigudosa JC,Garcia-Barbero M. Personalized Precision Medicine for Health Care Professionals:Development of a Competency Framework. JMIR Med Educ. 2023 Feb 7;9:e43656. doi:10.2196/43656. Erratum In: JMIR Med Educ. 2023 Feb 21;9:e46366. doi:10.2196/46366. PubMed PMID: 36749626; PubMed Central PMCID: PMC9943053.

Mendez-Vidal MJ, Lazaro Quintela M, Lainez-Milagro N, Perez-Valderrama B,Suarez Rodriguez C, Arranz Arija JA, Pelaez Fernandez I, Gallardo Diaz E, LambeaSorrosal J, Gonzalez-Del-Alba A. SEOM SOGUG clinical guideline for treatment ofkidney cancer (2022). Clin Transl Oncol. 2023 Sep;25(9):2732-2748. doi:10.1007/s12094-023-03276-5. Epub 2023 Aug 9. PubMed PMID: 37556095; PubMedCentral PMCID: PMC10425490.

Rapado-Gonzalez O, Brea-Iglesias J, Rodriguez-Casanova A, Bao-Caamano A,Lopez-Cedrun JL, Triana-Martinez G, Diaz-Pena R, Santos MA, Lopez-Lopez R,Muinelo-Romay L, Martinez-Fernandez M, Diaz-Lagares A, Suarez-Cunqueiro MM.Somatic mutations in tumor and plasma of locoregional recurrent and/or metastatichead and neck cancer using a next-generation sequencing panel: A preliminarystudy. Cancer Med. 2023 Mar;12(6):6615-6622. doi: 10.1002/cam4.5436. Epub 2022Nov 24. PubMed PMID: 36420687; PubMed Central PMCID: PMC10067107.

Sanchez Canovas M, Fernandez Garay D, Adoamnei E, Guirao Garcia E, LopezRobles J, Cacho Lavin D, Martinez de Castro E, Campos Balea B, Garrido FernandezA, Fernandez Perez I, Ferrandez Arias A, Suarez N, Quintanar Verduguez T, Lobo deMena M, Rodriguez L, Gutierrez D, Martin Fernandez de Soiginie AM, Garcia AdrianS, Ferrer Perez AI, Delgado Heredia MJ, Munoz Lerma A, Luque R, Mazariegos RubiM, Ruperez Blanco AB, Garcia Escobar I, Mendiola J, Munoz Martin AJ. Immunecheckpoint inhibitor-associated thrombosis in patients with bladder and kidneycancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis andcancer group. Clin Transl Oncol. 2023 Oct;25(10):3021-3031. doi:10.1007/s12094-023-03171-z. Epub 2023 Apr 10. PubMed PMID: 37036596; PubMedCentral PMCID: PMC10462495.

Santamarina-Garcia M, Brea-Iglesias J, Bramsen JB, Fuentes-Losada M,Caneiro-Gomez FJ, Vazquez-Bueno JA, Lazare-Iglesias H, Fernandez-Diaz N,Sanchez-Rivadulla L, Betancor YZ, Ferreiro-Pantin M, Conesa-Zamora P,Antunez-Lopez JR, Kawazu M, Esteller M, Andersen CL, Tubio JMC, Lopez-Lopez R,Ruiz-Banobre J. MSIMEP: Predicting microsatellite instability from microarray DNAmethylation tumor profiles. iScience. 2023 Feb 3;26(3):106127. doi:10.1016/j.isci.2023.106127. eCollection 2023 Mar 17. PubMed PMID: 36879816;PubMed Central PMCID: PMC9984554.

Elena Méndez. Respuesta mantenida al tratamiento de un paciente con carcinoma de pulmón metastásico sin mutaciones driver. Cambiando el concepto tradicional sobre el pronóstico en oncología. En: Libro de casos clínicos del 11º Curso de competencias en cáncer de pulmón 2023. Edición GECP. ISBN:978-84-09-50369-8. pp 76-77

Agraso S, Lazaro M, Firvida XL, Santome L, Fernandez N, Azpitarte C, Leon L,Garcia C, Hudobro G, Areses MC, Campos B, Quiroga N, Garcia J, Casal J.Real-world data with afatinib in Spanish patients with treatment-naivenon-small-cell lung cancer harboring exon 19 deletions in epidermal growth factorreceptor (Del19 EGFR): Clinical experience of the Galician Lung Cancer Group.Cancer Treat Res Commun. 2022;33:100646. doi: 10.1016/j.ctarc.2022.100646. Epub2022 Oct 4. PubMed PMID: 36335799.

Aguado de la Rosa C, Cruz Castellanos P, Lazaro-Quintela M, Domine M, VazquezEstevez S, Lopez-Vivanco G, Firvida Perez JL, Alonso Romero JL, Ferrera DelgadoL, Garcia Giron C, Diz Tain P, Alvarez Alvarez R, Mut Sanchis P, Fernandez CantonI, Manrique Abos I, Martinez Aguillo M, Gomez-Aldaravi Gutierrez L, OrtegaGranados AL, Alvarez Cabellos R, Garcia Sebastian A, Garcia Sifuentes LF, ReguartN. Identification of ALK-positive patients with advanced NSCLC and real-worldclinical experience with crizotinib in Spain (IDEALK study). Lung Cancer. 2022Nov;173:83-93. doi: 10.1016/j.lungcan.2022.09.010. Epub 2022 Sep 19. PubMed PMID:36162227.

Albanell J, Martinez MT, Ramos M, O’Connor M, de la Cruz-Merino L, SantaballaA, Martinez-Janez N, Moreno F, Fernandez I, Alarcon J, Virizuela JA, de laHaba-Rodriguez J, Sanchez-Rovira P, Gonzalez-Cortijo L, Margeli M, Sanchez-MunozA, Anton A, Casas M, Bezares S, Rojo F. Randomized phase II study of fulvestrantplus palbociclib or placebo in endocrine-sensitive, hormonereceptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER). Eur JCancer. 2022 Jan;161:26-37. doi: 10.1016/j.ejca.2021.11.010. Epub 2021 Dec 11.PubMed PMID: 34902765.

Carmona-Bayonas A, Verso M, Sanchez Canovas M, Rubio Perez J, Garcia deHerreros M, Martinez Del Prado P, Fernandez Perez I, Quintanar Verduguez T,Obispo Portero B, Pachon Olmos V, Gomez D, Ortega L, Serrano Moyano M, M BrozosE, Biosca M, Antonio Rebollo M, Teijeira Sanchez L, Hernandez Perez C, DavidCumplido Buron J, Martinez Lago N, Garcia Perez E, Munoz Langa J, Perez Segura P,Martinez de Castro E, Jimenez-Fonseca P, Agnelli G, Munoz A. Do AntiangiogenicsPromote Clot Instability? Data from the TESEO Prospective Registry and CaravaggioClinical Trial. Thromb Haemost. 2022 Oct;122(10):1653-1661. doi:10.1055/a-1816-8347. Epub 2022 Apr 5. PubMed PMID: 35381615; PubMed CentralPMCID: PMC9512585.

Carrasco Rodriguez R, Garcia Fontan EM, Blanco Ramos M, Magdalena BenavidesLJ, Otero Lozano D, Moldes Rodriguez M, Canizares Carretero MA. Inflammatorypseudotumor and myofibroblastic inflammatory tumor. Diagnostic criteria andprognostic differences. Cir Esp (Engl Ed). 2022 Jun;100(6):329-335. doi:10.1016/j.cireng.2022.05.012. Epub 2022 May 13. PubMed PMID: 35577280.

Casarrubios M, Provencio M, Nadal E, Insa A, Del Rosario Garcia-Campelo M,Lazaro-Quintela M, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, DeCastro Carpeno J, Cobo M, Lopez Vivanco G, Del Barco E, Bernabe R, Vinolas N,Barneto Aranda I, Massuti B, Sierra-Rodero B, Martinez-Toledo C,Fernandez-Miranda I, Serna-Blanco R, Romero A, Calvo V, Cruz-Bermudez A. Tumormicroenvironment gene expression profiles associated to complete pathologicalresponse and disease progression in resectable NSCLC patients treated withneoadjuvant chemoimmunotherapy. J Immunother Cancer. 2022 Sep;10(9):e005320. doi:10.1136/jitc-2022-005320. PubMed PMID: 36171009; PubMed Central PMCID:PMC9528578.

Climent MA, Font A, Duran I, Puente J, Jose Mendez-Vidal M, Saez MI, SantanderLobera C, Angel Arranz Arija J, Gonzalez-Del-Alba A, Sanchez-Hernandez A, JuanFita MJ, Esteban E, Alonso-Gordoa T, Mellado Gonzalez B, Maroto P,Lazaro-Quintela M, Cassinello-Espinosa J, Perez-Valderrama B, Garcias C,Castellano D. A phase II randomised trial of abiraterone acetate plus prednisonein combination with docetaxel or docetaxel plus prednisone after diseaseprogression to abiraterone acetate plus prednisone in patients with metastaticcastration-resistant prostate cancer: The ABIDO-SOGUG trial. Eur J Cancer. 2022Nov;175:110-119. doi: 10.1016/j.ejca.2022.08.002. Epub 2022 Sep 11. PubMed PMID:36099670.

Elumalai T, Croxford W, Buijtenhuijs B, Conroy R, Sanderson B, Enting D,Aversa C, Doss G, Das A, Vasudev NS, Kitetere E, Tolan S, Law A, Hoskin P, MistryH, Choudhury A. Using Real-world Data to Define a Validated Nomogram for AdvancedBladder Cancer Patients Who Respond to Immunotherapy. Clin Oncol (R Coll Radiol).2022 Oct;34(10):642-652. doi: 10.1016/j.clon.2022.02.022. Epub 2022 Mar 11.PubMed PMID: 35282933.

Fernandez Montes A, Elez E, Vivancos A, Martinez N, Gonzalez P, Covela M, dela Camara J, Cousillas A, Mendez JC, Grana B, Aranda E. Monitoring of RAS mutantclones in plasma of patients with RAS mutant metastatic colorectal cancer. ClinTransl Oncol. 2022 Jun;24(6):1209-1214. doi: 10.1007/s12094-021-02767-7. Epub2022 Jan 7. PubMed PMID: 34997474; PubMed Central PMCID: PMC9107427.

Fernandez O, Lazaro-Quintela M, Crespo G, Soto de Prado D, Pinto A,Basterretxea L, Gomez de Liano A, Etxaniz O, Blasco S, Gabas-Rivera C, AceitunoS, Palomar V, Polanco-Sanchez C. Preferences for Renal Cell CarcinomaPharmacological Treatment: A Discrete Choice Experiment in Patients andOncologists. Front Oncol. 2022 Jan 7;11:773366. doi: 10.3389/fonc.2021.773366.eCollection 2021. PubMed PMID: 35070976; PubMed Central PMCID: PMC8777125.

Fernandez Perez I, Tunas LV, Corbacho DP, Benito CG, Ojea CG, Fernandez AG,Silva MJV, Lorenzo IL, Rubio JC. Utility of Genomic Platforms in TreatmentDecisions in Axilla-Positive Breast Cancer. Clin Breast Cancer. 2022Oct;22(7):634-641. doi: 10.1016/j.clbc.2022.07.014. Epub 2022 Aug 5. PubMed PMID:36002343.

Guillem Porta V, Camps C, Climent Duran MA, Gallardo E, Gonzalez Del Alba A,Lazaro-Quintela M, Mendez Vidal MJ, Pinto Marin A, Puente J, Anton-Rodriguez C,Caballero-Martinez F, Campos-Lucas FJ, Lugo I, Rogado A, Duran I. Measures toevaluate quality of care in renal cancer: results of a Delphi study in Spain.Clin Transl Oncol. 2022 Mar;24(3):495-502. doi: 10.1007/s12094-021-02703-9. Epub2021 Sep 5. PubMed PMID: 34482526.

Jimenez N, Reig O, Marin-Aguilera M, Aversa C, Ferrer-Mileo L, Font A,Rodriguez-Vida A, Climent MA, Cros S, Chirivella I, Domenech M, Figols M,Gonzalez-Billalabeitia E, Jimenez Peralta D, Rodriguez-Carunchio L, Garcia-EsteveS, Garcia de Herreros M, Ribal MJ, Prat A, Mellado B. Transcriptional ProfileAssociated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate CancerTreated with Androgen Deprivation and Docetaxel. Cancers (Basel). 2022 Sep29;14(19):4757. doi: 10.3390/cancers14194757. PubMed PMID: 36230681; PubMedCentral PMCID: PMC9564355.

Losa F, Fernandez I, Etxaniz O, Gimenez A, Gomila P, Iglesias L, Longo F,Nogales E, Sanchez A, Soler G. SEOM-GECOD clinical guideline for unknown primarycancer (2021). Clin Transl Oncol. 2022 Apr;24(4):681-692. doi:10.1007/s12094-022-02806-x. Epub 2022 Mar 23. PubMed PMID: 35320504; PubMedCentral PMCID: PMC8986666.

Martinez-Lago N, Cameselle Garcia S, Alonso de Castro B, Gomez-RandulfeRodriguez MI, Carmona Campos M, Gonzalez Villarroel P, Salgado Fernandez M, De laCamara Gomez JC, Romero Reinoso C, Cousillas Castineiras A, Mendez Mendez JC,Vidal Insua Y, Fernandez-Montes A. Efficacy and safety of FOLFIRI/aflibercept(FA) in an elderly population with metastatic colorectal cancer (mCRC) afterfailure of an oxaliplatin-based regimen. PLoS One. 2022 Jun 3;17(6):e0269399.doi: 10.1371/journal.pone.0269399. eCollection 2022. PubMed PMID: 35657983;PubMed Central PMCID: PMC9165891.

Oitaben A, Fonseca P, Villanueva MJ, Garcia-Benito C, Lopez-Lopez A,Garrido-Fernandez A, Gonzalez-Ojea C, Juaneda-Magdalena L, Lazaro ME,Martinez-Fernandez M. Emerging Blood-Based Biomarkers for PredictingImmunotherapy Response in NSCLC. Cancers (Basel). 2022 May 26;14(11):2626. doi:10.3390/cancers14112626. PubMed PMID: 35681606; PubMed Central PMCID: PMC9179588.

Perez IF, Valverde D, Valverde CF, Iglesias JB, Silva MJV, Quintela ML,Melendez B. An analysis of prognostic factors in a cohort of low-grade gliomasand degree of consistency between RTOG and EORTC scores. Sci Rep. 2022 Sep30;12(1):16433. doi: 10.1038/s41598-022-20429-8. PubMed PMID: 36180501; PubMedCentral PMCID: PMC9525658.

Pinto A, Reig O, Iglesias C, Gallardo E, Garcia-Del Muro X, Alonso T, AngueraG, Suarez C, Munoz-Langa J, Villalobos-Leon L, Rodriguez-Sanchez A, Lainez N,Martinez-Ortega E, Campayo M, Velastegui A, Rodriguez-Vida A, Villa-Guzman JC,Mendez-Vidal MJ, Rubio G, Garcia I, Capdevila L, Lambea J, Vazquez S, FernandezO, Hernando-Polo S, Cerezo S, Santander C, Garcia-Marrero R, Zambrana F,Gonzalez-Del Alba A, Lazaro-Quintela M, Castellano D, Chirivella I, Anido U,Viana A, Garcia A, Sotelo M, Arevalo MG, Garcia-Donas J, Hernandez C, Bolos MV,Llinares J, Climent MA. Clinical Factors Associated With Long-Term Benefit inPatients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-WorldAXILONG Study. Clin Genitourin Cancer. 2022 Feb;20(1):25-34. doi:10.1016/j.clgc.2021.09.006. Epub 2021 Oct 20. PubMed PMID: 34789409.

Provencio M, Cobo M, Rodriguez-Abreu D, Calvo V, Carcereny E, Cantero A,Bernabe R, Benitez G, Castro RL, Massuti B, Del Barco E, Garcia Campelo R,Guirado M, Camps C, Ortega AL, Gonzalez Larriba JL, Sanchez A, Casal J, Sala MA,Juan-Vidal O, Bosch-Barrera J, Oramas J, Domine M, Trigo JM, Blanco R, Calzas J,Morilla I, Padilla A, Pimentao J, Sousa PA, Torrente M. Determination ofessential biomarkers in lung cancer: a real-world data study in Spain withdemographic, clinical, epidemiological and pathological characteristics. BMCCancer. 2022 Jul 5;22(1):732. doi: 10.1186/s12885-022-09830-8. PubMed PMID:35790916; PubMed Central PMCID: PMC9254518.

Provencio M, Serna-Blasco R, Nadal E, Insa A, Garcia-Campelo MR, Casal RubioJ, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeno J,Cobo M, Lopez Vivanco G, Del Barco E, Bernabe Caro R, Vinolas N, Barneto ArandaI, Viteri S, Pereira E, Royuela A, Calvo V, Martin-Lopez J, Garcia-Garcia F,Casarrubios M, Franco F, Sanchez-Herrero E, Massuti B, Cruz-Bermudez A, Romero A.Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab PlusChemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase IItrial). J Clin Oncol. 2022 Sep 1;40(25):2924-2933. doi: 10.1200/JCO.21.02660.Epub 2022 May 16. Erratum In: J Clin Oncol. 2022 Nov 10;40(32):3785. PubMed PMID:35576508; PubMed Central PMCID: PMC9426809.

Remon J, Bernabe R, Diz P, Felip E, Gonzalez-Larriba JL, Lazaro M,Mielgo-Rubio X, Sanchez A, Sullivan I, Massutti B. SEOM-GECP-GETTHI ClinicalGuidelines for the treatment of patients with thymic epithelial tumours (2021).Clin Transl Oncol. 2022 Apr;24(4):635-645. doi: 10.1007/s12094-022-02788-w. Epub2022 Feb 5. PubMed PMID: 35122634; PubMed Central PMCID: PMC8817662.

Salgado M, Brozos-Vazquez E, Campos B, Gonzalez-Villarroel P, Perez ME,Vazquez-Tunas ML, Arias D. Venous Thromboembolism In Cancer Patients: «FromEvidence to Care». Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221098717.doi: 10.1177/10760296221098717. PubMed PMID: 35538861; PubMed Central PMCID:PMC9102132.

Suarez-Cabrera C, Estudillo L, Ramon-Gil E, Martinez-Fernandez M, Peral J,Rubio C, Lodewijk I, Martin de Bernardo A, Garcia-Escudero R, Villacampa F,Duarte J, de la Rosa F, Castellano D, Guerrero-Ramos F, Real FX, Malats N,Paramio JM, Duenas M. BlaDimiR: A Urine-based miRNA Score for Accurate BladderCancer Diagnosis and Follow-up. Eur Urol. 2022 Dec;82(6):663-667. doi:10.1016/j.eururo.2022.08.011. Epub 2022 Sep 6. No abstract available. PubMedPMID: 36085102.

Vallejo Casas JA, Sambo M, Lopez Lopez C, Duran-Poveda M, Rodriguez-VillanuevaGarcia J, Santos RJ, Llanos M, Navarro-Gonzalez E, Aller J, Pubul V, Guadalix S,Crespo G, Gonzalez C, Zafon C, Navarro M, Santamaria-Sandi J, Segura A, Gajate P,Gomez-Balaguer M, Valdivia J, Puig-Domingo M, Galofre JC, Castelo B, VillanuevaMJ, Arguelles I, Orcajo-Rincon L. Initial clinical and treatment patterns ofadvanced differentiated thyroid cancer: ERUDIT study. Eur Thyroid J. 2022 Aug11;11(5):e210111. doi: 10.1530/ETJ-21-0111. Print 2022 Oct 1. PubMed PMID:35900793; PubMed Central PMCID: PMC9422238.

Villarroel PG, Padro JG, Marquina G, Janez NM, Gonzalez EE, Anton A, SanchezMB, Caceres AR, Lopez-Lopez R, Cornejo RE, Garcia PB, Fabregat RM, Fernandez BC,Bermudo CL, Camps C. Increased quality of life in patients with breakthroughcancer pain after individualized therapy: the CAVIDIOM study. Future Oncol. 2022Nov;18(35):3913-3927. doi: 10.2217/fon-2022-0758. Epub 2022 Dec 20. PubMed PMID:36537885.

Bañón Torres D, Méndez Carrascosa ER, Iglesias Beirosa A, Galera Rodríguez P, Castillo Fernández L, Arangoa Caro T, Álvarez Maldonado-Trabucchelli M, Gil-Olarte Montesinos CM, Arregui Valles M, Álvarez Álvarez R. Tumor de Wilms en el adulto. Un ejemplo de la relevancia del estudiohistológico en la patología oncológica. En libro 16º Concurso SEOM de casos clínicos 2022. Edición: Sociedad Española de Oncología Medica. ISBN: 978-84-09-53248-3. pp 793-795.

Castillo Fernández L, Méndez Carrascosa ER, Arangoa Caro T, Iglesias Beiroa A, Galera Rodríguez P, Bañón Torres D, Álvarez Maldonado-Trabucchelli M, Gil-Olarte Montesinos CM. Síndrome de encefalopatía posterior reversible secundario a bevacizumab y papel de la hipomagnesemia en su fisiopatología. En libro 16º Concurso SEOM de casos clínicos 2022. Edición: Sociedad Española de Oncología Medica. ISBN:978-84-09-53248-3. pp 343-345.

Iglesias Beiroa A, Bañón Torres D, Galera Rodríguez P, Castillo FernándezL, Arangoa Caro T, Méndez-Carrascosa ER. Estrategia de Rechallenge en carcinoma de colon metastásico en la práctica clínica diaria. En libro 15º Concurso SEOM de casosclínicos 2022. Edición: Sociedad Española de Oncología Medica. ISBN: 978-84-09-43885-3.2022. pp 484-486.

Iglesias Beiroa A, Galera Rodríguez P, Bañón Torres D, Méndez Carrascosa ER, CastilloFernández L, Arangoa Caro T, Álvarez Maldonado-Trabucchelli M, Gil-Olarte MontesinosCM, Garrido García A. Inmunoterapia en cáncer renal cromófobo: ¿beneficio o riesgo en ancianos? En libro 16º Concurso SEOM de casos clínicos 2022. Edición: Sociedad Española de Oncología Medica. ISBN: 978-84-09-53248-3. pp 283-285.

Méndez-Carrascosa ER, Garrido García A,Bañón Torres D, Iglesias Beirosa A, Galera Rodríguez P, Arangoa Caro T, CastilloFernández L, Gil-Olarte Montesinos CM, Álvarez Maldonado-Trabucchelli M, Costas RojoP. Paniculitis pancreática inmunomediada como toxicidad tardía tras suspendertratamiento con inmunoterapia. En libro 16º Concurso SEOM de casos clínicos 2022. Edición: Sociedad Española de Oncología Medica . ISBN: 978-84-09-53248-3. pp 443-445.

Carcinoma gástrico. Elena Rosalía Méndez Carrascosa. Aplicación móvilOncorama. Manual del Hospital de La Princesa para residentes de Oncología Médica.Edición: P. Permanyer. 2022. ISBN: 978-84-19418-19-7.

Álvarez EG, Demeulemeester J, Otero P, Jolly C, García-Souto D, Pequeño-Valtierra A, Zamora J, Tojo M, Temes J, Baez-Ortega A, Rodriguez-Martin B, Oitaben A, Bruzos AL, Martínez-Fernández M, Haase K, Zumalave S, Abal R, Rodríguez-Castro J, Rodriguez-Casanova A, Diaz-Lagares A, Li Y, Raine KM, Butler AP, Otero I, Ono A, Aikata H, Chayama K, Ueno M, Hayami S, Yamaue H, Maejima K, Blanco MG, Forns X, Rivas C, Ruiz-Bañobre J, Pérez-Del-Pulgar S, Torres-Ruiz R, Rodriguez-Perales S, Garaigorta U, Campbell PJ, Nakagawa H, Van Loo P, Tubio JMC. Aberrant integration of Hepatitis B virus DNA promotes major restructuring of human hepatocellular carcinoma genome architecture. Nat Commun. 2021;12(1):6910. PMID: 34824211. DOI: 10.1038/s41467-021-26805-8. http://www.ncbi.nlm.nih.gov/pubmed/34824211
Enlace

Arias Ron D, Areses Manrique MC, Mosquera Martínez J, García González J, Afonso Afonso FJ, Lázaro Quintela M, Fernández Núñez N, Azpitarte Raposeiras C, Amenedo Gancedo M, Santomé Couto L, García Campelo MR, Muñoz Iglesias J, Ruiz Bañobre J, Vilchez Simo R, Casal Rubio J, Campos Balea B, Carou Frieiro I, Alonso-Jaudenes Curbera G, Anido Herranz U, García Mata J, Fírvida Pérez JL. Efficacy and safety of Nivolumab in older patients with pretreated lung cancer: A subgroup analysis of the Galician lung cancer group. J Geriatr Oncol. 2021 Apr;12(3):410–5. PMID: 33357975. DOI: 10.1016/j.jgo.2020.11.010. http://www.ncbi.nlm.nih.gov/pubmed/33357975
Enlace

Fernández Montes A, Martinez-Lago N, de la Cámara Gomez J, Brozos Vázquez EM, Candamio Folgar S, Carmona Campos M, Cousillas Castiñeiras A, Covela Rúa M, Gallardo Martín E, González Villarroel P, Graña Suarez B, Jorge Fernández M, Pellón Augusto ML, Quintero Aldana G, Romero Reinoso C, Salgado Fernández M, Vázquez Rivera F, Ayuso Álvarez A, Culqui DR, Méndez Méndez JC, RIGhT-Sens Working Group. Do Clinical Trials Meet Current Care Needs? Views of Digestive Oncology Specialists in Galicia (Spain) Using the Delphi Method. Healthc (Basel, Switzerland). 2021 Jun;9(6):665. PMID: 34205026. DOI: 10.3390/healthcare9060665. http://www.ncbi.nlm.nih.gov/pubmed/34205026
Enlace

Gil V, Miranda S, Riisnaes R, Gurel B, D’Ambrosio M, Vasciaveo A, Crespo M,Ferreira A, Brina D, Troiani M, Sharp A, Sheehan B, Christova R, Seed G,Figueiredo I, Lambros M, Dolling D, Rekowski J, Alajati A, Clarke M, Pereira R,Flohr P, Fowler G, Boysen G, Sumanasuriya S, Bianchini D, Rescigno P, Aversa C,Tunariu N, Guo C, Paschalis A, Bertan C, Buroni L, Ning J, Carreira S, Workman P,Swain A, Califano A, Shen MM, Alimonti A, Neeb A, Welti J, Yuan W, de Bono J;PCF/SU2C International Prostate Cancer Dream Team. HER3 Is an Actionable Targetin Advanced Prostate Cancer. Cancer Res. 2021 Dec 15;81(24):6207-6218. doi:10.1158/0008-5472.CAN-21-3360. Epub 2021 Nov 9. PubMed PMID: 34753775; PubMedCentral PMCID: PMC8932336.

Majem M, Cobo M, Isla D, Marquez-Medina D, Rodriguez-Abreu D, Casal-Rubio J, Bueno TM, Bernabé-Caro R, Parente DP, Ruiz-Gracia P, Arroyo MM, Paz-Ares L. PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis. J Clin Med. 2021 Mar;10(7):1365. PMID: 33810441. DOI: 10.3390/jcm10071365. http://www.ncbi.nlm.nih.gov/pubmed/33810441
Enlace

Marin-Aguilera M, Pereira MV, Jimenez N, Reig O, Cuartero A, Victoria I,Aversa C, Ferrer-Mileo L, Prat A, Mellado B. Glutamine and Cholesterol PlasmaLevels and Clinical Outcomes of Patients with Metastatic Castration-ResistantProstate Cancer Treated with Taxanes. Cancers (Basel). 2021 Oct 1;13(19):4960.doi: 10.3390/cancers13194960. PubMed PMID: 34638444; PubMed Central PMCID:PMC8507765.

Martínez-Lago N, Fernández-Montes A, Covela M, Brozos EM, De la Cámara J, Méndez Méndez JC, Jorge-Fernández M, Cousillas Castiñeiras A, Reboredo C, Arias Ron D, Pellón Augusto ML, González Villarroel P, Graña B, Salgado Fernández M, Carral Maseda A, Vázquez Rivera F, Candamio Folgar S, Reboredo López M, Galician Research Group on Digestive Tumors (GITuD). Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain. BMC Cancer. 2021 Jan;21(1):64. PMID: 33446148. DOI: 10.1186/s12885-020-07758-5. http://www.ncbi.nlm.nih.gov/pubmed/33446148
Enlace

Martínez-Trufero J, De Sande-González LM, Luna P, Martin-Broto J, Álvarez R, Marquina G, Diaz-Beveridge R, Poveda A, Cano JM, Cruz-Jurado J, López Pousa A, Vaz Salgado MA, Valverde-Morales CM, Sevilla I, Martínez-García J, Rubio-Casadevall J, De Juan A, Carrasco JA, Moura DS, Gurruchaga-Sotes I, Gutiérrez A. A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study. Cancers (Basel). 2021 Feb;13(4) PMID: 33672857. DOI: 10.3390/cancers13040792. http://www.ncbi.nlm.nih.gov/pubmed/33672857
Enlace

Neeb A, Herranz N, Arce-Gallego S, Miranda S, Buroni L, Yuan W, Athie A,Casals T, Carmichael J, Rodrigues DN, Gurel B, Rescigno P, Rekowski J, Welti J,Riisnaes R, Gil V, Ning J, Wagner V, Casanova-Salas I, Cordoba S, Castro N, Fenorde la Maza MD, Seed G, Chandran K, Ferreira A, Figueiredo I, Bertan C, BianchiniD, Aversa C, Paschalis A, Gonzalez M, Morales-Barrera R, Suarez C, Carles J,Swain A, Sharp A, Gil J, Serra V, Lord C, Carreira S, Mateo J, de Bono JS.Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors. Eur Urol. 2021Feb;79(2):200-211. doi: 10.1016/j.eururo.2020.10.029. Epub 2020 Nov 8. PubMedPMID: 33176972.

Pereira-Veiga T, González-Conde M, León-Mateos L, Piñeiro-Cid R, Abuín C, Muinelo-Romay L, Martínez-Fernández M, Brea Iglesias J, García González J, Anido U, Aguín-Losada S, Cebey V, Costa C, López-López R. Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers. Clin Exp Metastasis. 2021 Apr;38(2):239–51. PMID: 33635497. DOI: 10.1007/s10585-021-10075-1. http://www.ncbi.nlm.nih.gov/pubmed/33635497
Enlace

Ribelles N, Alvarez-Lopez I, Arcusa A, Chacon JI, de la Haba J, García-Corbacho J, Garcia-Mata J, Jara C, Jerez JM, Lázaro-Quintela M, Leon-Mateos L, Ramirez-Merino N, Tibau A, Garcia-Palomo A. Electronic health records and patient registries in medical oncology departments in Spain. Clin Transl Oncol. 2021 Oct;23(10):2099–108. PMID: 33864619. DOI: 10.1007/s12094-021-02614-9. http://www.ncbi.nlm.nih.gov/pubmed/33864619
Enlace

Ruiz-Bañobre J, Molina-Díaz A, Fernández-Calvo O, Fernández-Núñez N, Medina-Colmenero A, Santomé L, Lázaro-Quintela M, Mateos-González M, García-Cid N, López-López R, Vázquez S, Anido-Herranz U. Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study. ESMO open. 2021 Apr;6(2):100090. PMID: 33740735. DOI: 10.1016/j.esmoop.2021.100090. http://www.ncbi.nlm.nih.gov/pubmed/33740735
Enlace

Toquero P, Blanco Fernandez C, Lopez Marti MP, Hernandez Marin B, Vera Cea EB,Garrido Garcia A, Mendez Carrascosa E, Banon Torres D, Donnay Candil O,Ballesteros Garcia AI, Sanchez-Torres JM, Costas Rojo P, Mondejar R, Colomer R,Romero-Laorden N. Emotional Distress in Cancer Patients During the First Wave ofthe COVID-19 Pandemic. Front Psychol. 2021 Nov 5;12:755965. doi:10.3389/fpsyg.2021.755965. eCollection 2021. PubMed PMID: 34803837; PubMedCentral PMCID: PMC8602105.

Ana Isabel Ballesteros García y Elena Rosalía Méndez Carrascosa. Tratamiento de la anemia secundaria a quimioterapia neoadyuvante de cáncer de mama. En: «Experiencias clínicas en anemia y cáncer. Principios del tratamiento de la anemia en el paciente con cáncer». ISSN 2696-5003

David Martín García. Inmunoterapia en adenocarcinoma gástrico metastásico, nuevos horizontes en el tratamiento de los tumores gástricos. Casos Clínicos de Oncología Médica,. pp. 125 – 128. Fundación Merck Salud, 2021.

José Enrique Alés Martínez, Raquel Andrés Conejero, Carmen Guillén Ponce, Isabel Lorenzo Lorenzo, Teresa Martín Gómez. Rafael Morales Chamorro. Teresa Ramón y Cajal Asensio. Ana Beatriz Sánchez Heras. Situación del Cáncer Hereditario en España. Sociedad Española de Oncología Médica (SEOM), 2021. ISBN: 78-84-09-34640-0

Martín Lázaro Quintela. Detección precoz de las toxicidades agudas del tratamiento: signos, síntomas y datos de laboratorio. En: Situaciones especiales clínicas en carcinoma renal. Springer 2021. ISBN: 978-84-09-27636-3

Méndez Carrascosa ER, Hernández Marín B, Toquero Díez P, Garrido García A, Bañón Torres D, Galera Rodríguez P, Iglesias Beiroa A. Tratamiento sistémico del paraganglioma: a propósito de un caso. En libro 14º Concurso SEOM de casos clínicos 2021. Edición: Sociedad Española de Oncología Medica. ISBN: 978-84-09-33851-1. 2021. pp. 690-693.

Carmona-Bayonas A, Gómez D, Martínez de Castro E, Pérez Segura P, Muñoz Langa J, Jimenez-Fonseca P, Sánchez Cánovas M, Ortega Moran L, García Escobar I, Rupérez Blanco AB, Fernández Pérez I, Martínez de Prado P, Porta I Balanyà R, Quintanar Verduguez T, Rodríguez-Lescure Á, Muñoz A. A snapshot of cancer-associated thromboembolic disease in 2018-2019: First data from the TESEO prospective registry. Eur J Intern Med. 2020 Aug;78:41–9. PMID: 32482596. DOI: 10.1016/j.ejim.2020.05.031. http://www.ncbi.nlm.nih.gov/pubmed/32482596
Enlace

Carvalho S, Abreu CM, Ferreira D, Lima L, Ferreira JA, Santos LL, Ribeiro R, Grenha V, Martínez-Fernández M, Duenas M, Suárez-Cabrera C, Paramio JM, Diéguez L, Freitas PP, Oliveira MI. Phenotypic Analysis of Urothelial Exfoliated Cells in Bladder Cancer via Microfluidic Immunoassays: Sialyl-Tn as a Novel Biomarker in Liquid Biopsies. Front Oncol. 2020;10:1774. PMID: 33042825. DOI: 10.3389/fonc.2020.01774. http://www.ncbi.nlm.nih.gov/pubmed/33042825
Enlace

Fernandez Montes A, Vazquez Rivera F, Martinez Lago N, Covela Rúa M, Cousillas Castiñeiras A, Gonzalez Villarroel P, de la Cámara Gómez J, Méndez Méndez JC, Salgado Fernández M, Candamio Folgar S, Reboredo López M, Carmona Campos M, Gallardo Martín E, Jorge Fernández M, Pellón Augusto ML, París Bouzas L, García Gómez J. Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram. Clin Transl Oncol. 2020 Mar;22(3):351–9. PMID: 31073972. DOI: 10.1007/s12094-019-02130-x. http://www.ncbi.nlm.nih.gov/pubmed/31073972
Enlace

García-González J, Ruiz-Bañobre J, Afonso-Afonso FJ, Amenedo-Gancedo M, Areses-Manrique MDC, Campos-Balea B, Casal-Rubio J, Fernández-Núñez N, Fírvida Pérez JL, Lázaro-Quintela M, Pérez Parente D, Crama L, Ruiz-Gracia P, Santomé-Couto L, León-Mateos L. PD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysis. J Clin Med. 2020 Jul;9(7):2093. PMID: 32635291. DOI: 10.3390/jcm9072093. http://www.ncbi.nlm.nih.gov/pubmed/32635291
Enlace

González-Del-Alba A, Arranz JÁ, Bellmunt J, Maroto JP, Fernández-Calvo O, Valderrama BP, González-Billalabeitia E, Méndez-Vidal MJ, Cassinello J, Romero-Laorden N, Climent MÁ, Puente J, Peláez I, Lázaro-Quintela M, Gallardo E, Suárez C. Latest progress in molecular biology and treatment in genitourinary tumours. Clin Transl Oncol. 2020 Dec;22(12):2175–95. PMID: 32440915. DOI: 10.1007/s12094-020-02373-z. http://www.ncbi.nlm.nih.gov/pubmed/32440915
Enlace

Guillén-Ponce C, Lastra E, Lorenzo-Lorenzo I, Martín Gómez T, Morales Chamorro R, Sánchez-Heras AB, Serrano R, Soriano Rodríguez MC, Soto JL, Robles L. SEOM clinical guideline on hereditary colorectal cancer (2019). Clin Transl Oncol. 2020 Feb;22(2):201–12. PMID: 31981079. DOI: 10.1007/s12094-019-02272-y. http://www.ncbi.nlm.nih.gov/pubmed/31981079
Enlace

Isla D, Massuti B, Lázaro M, de Alda LR, Gordo R, Ortega-Joaquín N, Oyagüez I. Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib. Lung Cancer Manag. 2020 Mar;9(1):LMT28. PMID: 32256712. DOI: 10.2217/lmt-2019-0011. http://www.ncbi.nlm.nih.gov/pubmed/32256712
Enlace

Lázaro M, Valderrama BP, Suárez C, De-Velasco G, Beato C, Chirivella I, González-Del-Alba A, Laínez N, Méndez-Vidal MJ, Arranz JA. SEOM clinical guideline for treatment of kidney cancer (2019). Clin Transl Oncol. 2020 Feb;22(2):256–69. PMID: 31993962. DOI: 10.1007/s12094-019-02285-7. http://www.ncbi.nlm.nih.gov/pubmed/31993962
Enlace

Lluch A, Barrios CH, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J, Guerrero-Zotano Á, García-Sáenz JA, Torres R, de la Haba J, García-Martínez E, Gómez HL, Llombart A, Bofill JS, Baena-Cañada JM, Barnadas A, Calvo L, Pérez-Michel L, Ramos M, Fernández I, Rodríguez-Lescure Á, Cárdenas J, Vinholes J, Martínez de Dueñas E, Godes MJ, Seguí MA, Antón A, López-Álvarez P, Moncayo J, Amorim G, Villar E, Reyes S, Sampaio C, Cardemil B, Escudero MJ, Bezares S, Carrasco E, Martín M, GEICAM Spanish Breast Cancer Group, CIBOMA (Iberoamerican Coalition for Research in Breast Oncology), LACOG (Latin American Cooperative Oncology Group). Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). J Clin Oncol. 2020;38(3):203–13. PMID: 31804894. DOI: 10.1200/JCO.19.00904. http://www.ncbi.nlm.nih.gov/pubmed/31804894
Enlace

Méndez Méndez JC, Salgado Fernández M, de la Cámara Gómez J, Pellón Augusto ML, Covela Rua M, Quintero Aldana G, Fernández Montes A, Reboredo López M, Valladares Ayerbes M, Jorge Fernández M, González Villarroel P, Romero Reinoso C, Ramos Vázquez M, Galician Research Group on Digestive Tumours (GITuD). First-line panitumumab plus capecitabine for the treatment of older patients with wild-type RAS metastatic colorectal cancer. The phase II, PANEL study. J Geriatr Oncol. 2020;11(8):1263–7. PMID: 32580916. DOI: 10.1016/j.jgo.2020.06.003. http://www.ncbi.nlm.nih.gov/pubmed/32580916
Enlace

Provencio M, Nadal E, Insa A, García-Campelo MR, Casal-Rubio J, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Pereira E, Royuela A, Casarrubios M, Salas Antón C, Parra ER, Wistuba I, Calvo V, Laza-Briviesca R, Romero A, Massuti B, Cruz-Bermúdez A. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(11):1413–22. PMID: 32979984. DOI: 10.1016/S1470-2045(20)30453-8. http://www.ncbi.nlm.nih.gov/pubmed/32979984
Enlace

Quintero Aldana G, Salgado M, Candamio S, Méndez JC, Jorge M, Reboredo M, Vázquez Tuñas L, Romero C, Covela M, Fernández Montes A, Carmona M, Vidal Insua Y, López R, Galician Oncological Research Group (GGIO). First-line panitumumab plus docetaxel and cisplatin in advanced gastric and gastro-oesophageal junction adenocarcinoma: results of a phase II trial. Clin Transl Oncol. 2020 Apr;22(4):495–502. PMID: 31280434. DOI: 10.1007/s12094-019-02151-6. http://www.ncbi.nlm.nih.gov/pubmed/31280434
Enlace

Rescigno P, Aversa C, Crespo M, Seed G, Lambros M, Gurel B, Figueiredo I,Bianchini D, Riisnaes R, Pereira R, Fenor de la Maza MD, Carmichael J, ChandranK, Ferreira A, Bertan C, Paschalis A, Curcean A, Sharp A, Yuan W, Tunariu N,Poehlein C, Carreira S, de Bono JS. Elucidating Durable Responses to ImmuneCheckpoint Inhibition. Eur Urol. 2020 Oct;78(4):639-641. doi:10.1016/j.eururo.2020.06.056. Epub 2020 Jul 9. No abstract available. PubMedPMID: 32653323.

Ruano-Raviña A, Provencio M, Calvo de Juan V, Carcereny E, Moran T, Rodriguez-Abreu D, López-Castro R, Cuadrado Albite E, Guirado M, Gómez González L, Massutí B, Ortega Granados AL, Blasco A, Cobo M, Garcia-Campelo R, Bosch J, Trigo J, Juan Ó, Aguado de la Rosa C, Dómine M, Sala M, Oramas J, Casal-Rubio J, Cerezo S. Lung cancer symptoms at diagnosis: results of a nationwide registry study. ESMO open. 2020;5(6):e001021. PMID: 33214227. DOI: 10.1136/esmoopen-2020-001021. http://www.ncbi.nlm.nih.gov/pubmed/33214227
Enlace

Vázquez Estévez S, Anido U, Lázaro M, Fernández O, Fernández Núñez N, de Dios Álvarez N, Varela V, Campos Balea B, Agraso S, Areses MC, Iglesias L, Blanco M, Maciá S, Anton Aparicio LM. A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus. Clin Transl Oncol. 2020 Sep;22(9):1565–79. PMID: 32062835. DOI: 10.1007/s12094-020-02300-2. http://www.ncbi.nlm.nih.gov/pubmed/32062835
Enlace

Bañón D, Toquero P, Garrido A, Méndez E. Trombosis arterial crítica de rápida instauración en el contexto de tratamiento con Cisplatino. En libro 13º Concurso SEOMde casos clínicos 2020. Edición: Sociedad Española de Oncología Medica. ISBN: 978-84-09-24329-7. 2020. pp. 89-91

David Martín García. Carcinoma cromófobo de células renales. Secuencias y nuevas oportunidades detratamiento. Casos Clínicos de Oncología Médica. pp. 27 – 30. Fundación Merck Salud, 2020.

Garrido García A, García-Gil García JC, Silva Fernández M, ToqueroDíez P, Méndez-Carrascosa ER. Hipofisitis inducida por inmunoterapia, la importancia de un diagnóstico y tratamiento precoz. En libro 13º Concurso SEOM de casos clínicos 2020. Edición: Sociedad Española de Oncología Medica. ISBN: 978-84-09-24329-7.2020.pp.89-91.

Méndez-Carrascosa ER, Romero Laorden N, Vera Cea EB, Toquero Díez P, Garrido García A, Bañón Torres D, Fox B. Uso de pembrolizumab en adenocarcinoma endometrioide metastásico: un ejemplo actual de la oncología de precisión. En libro 13º Concurso SEOM de casos clínicos 2020. Edición: Sociedad Española de Oncología Medica. ISBN: 978-84-09-24329-7.

Toquero Díez P, Vera Cea B, Garrido García A, Méndez-Carrascosa ER, Bañón Torres D. Abordaje nutricional y cuidados paliativos. La nutrición parenteral domiciliaria al final de la vida, a propósito de un caso. En libro 13º Concurso SEOM de casos clínicos 2020. Edición: Sociedad Española de Oncología Medica. ISBN: 978-84-09-24329-7. 2020. pp. 89-91

Anido-Herranz U, Fernández-Núñez N, Afonso-Afonso J, Santomé-Couto L, Medina-Colmenero A, Fernández-Calvo O, Lázaro-Quintela M, Vázquez S. Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer. Clin Transl Oncol. 2019 Mar;21(3):249–58. PMID: 30051212. DOI: 10.1007/s12094-018-1928-y. http://www.ncbi.nlm.nih.gov/pubmed/30051212
Enlace

Conde E, Hernandez S, Martinez R, Angulo B, De Castro J, Collazo-Lorduy A, Jimenez B, Muriel A, Mate JL, Moran T, Aranda I, Massuti B, Rojo F, Domine M, Sansano I, Garcia F, Felip E, Mancheño N, Juan O, Sanz J, Gonzalez-Larriba JL, Atienza-Cuevas L, Arriola-Arellano E, Abdulkader I, Garcia-Gonzalez J, Camacho C, Rodriguez-Abreu D, Teixido C, Reguart N, Gonzalez-Piñeiro A, Lazaro-Quintela M, Lozano MD, Gurpide A, Gomez-Roman J, Lopez-Brea M, Pijuan L, Salido M, Arriola E, Company A, Insa A, Esteban-Rodriguez I, Saiz M, Azkona E, Alvarez R, Artal A, Plaza ML, Aguiar D, Enguita AB, Benito A, Paz-Ares L, Garrido P, Lopez-Rios F. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study. J Thorac Oncol. 2019;14(12):2120–32. PMID: 31349061. DOI: 10.1016/j.jtho.2019.07.005. http://www.ncbi.nlm.nih.gov/pubmed/31349061
Enlace

Dueñas M, Pérez-Figueroa A, Oliveira C, Suárez-Cabrera C, Sousa A, Oliveira P, Villacampa F, Paramio JM, Martínez-Fernández M. Gene Expression Analyses in Non Muscle Invasive Bladder Cancer Reveals a Role for Alternative Splicing and Tp53 Status. Sci Rep. 2019;9(1):10362. PMID: 31316092. DOI: 10.1038/s41598-019-46652-4. http://www.ncbi.nlm.nih.gov/pubmed/31316092
Enlace

Fernández Montes A, Martínez Lago N, Covela Rúa M, de la Cámara Gómez J, González Villaroel P, Méndez Méndez JC, Jorge Fernández M, Salgado Fernández M, Reboredo López M, Quintero Aldana G, Luz Pellón Augusto M, Graña Suárez B, García Gómez J. Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers. Cancer Med. 2019 Mar;8(3):882–9. PMID: 30690930. DOI: 10.1002/cam4.1903. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434192/pdf/CAM4-8-882.pdf
Enlace

Leiro-Fernández V, Mouronte-Roibás C, García-Rodríguez E, Botana-Rial M, Ramos-Hernández C, Torres-Durán M, Ruano-Raviña A, Fernández-Villar A, Lung Cancer Group at the Álvaro Cunqueiro Hospital in Vigo (Manuel Núñez?Delgado; Carlos Vilariño?Pombo; Ana González?Piñeiro; Eva García?Fontán; Montserrat Blanco?Ramos; Miguel Ángel Cañizares?Carretero; Paula Rodríguez?Fernández; Amara Tilve?Gómez; Elen. Predicting delays in lung cancer diagnosis and staging. Thorac cancer. 2019 Feb;10(2):296–303. PMID: 30605236. DOI: 10.1111/1759-7714.12950. http://www.ncbi.nlm.nih.gov/pubmed/30605236
Enlace

Martinez VG, Munera-Maravilla E, Bernardini A, Rubio C, Suarez-Cabrera C, Segovia C, Lodewijk I, Dueñas M, Martínez-Fernández M, Paramio JM. Epigenetics of Bladder Cancer: Where Biomarkers and Therapeutic Targets Meet. Front Genet. 2019;10:1125. PMID: 31850055. DOI: 10.3389/fgene.2019.01125. http://www.ncbi.nlm.nih.gov/pubmed/31850055
Enlace

Muñoz E, Domingo J, De Castro G, Lorenzo I, García-Velasco JA, Bellver J, Pellicer A, Garrido N. Ovarian stimulation for oocyte vitrification does not modify disease-free survival and overall survival rates in patients with early breast cancer. Reprod Biomed Online. 2019 Nov;39(5):860–7. PMID: 31564650. DOI: 10.1016/j.rbmo.2019.07.003. http://www.ncbi.nlm.nih.gov/pubmed/31564650
Enlace

Pereira-Veiga T, Martínez-Fernández M, Abuin C, Piñeiro R, Cebey V, Cueva J, Palacios P, Blanco C, Muinelo-Romay L, Abalo A, Costa C, López-López R. CTCs Expression Profiling for Advanced Breast Cancer Monitoring. Cancers (Basel). 2019 Dec;11(12) PMID: 31817194. DOI: 10.3390/cancers11121941. http://www.ncbi.nlm.nih.gov/pubmed/31817194
Enlace

Provencio M, Carcereny E, Rodríguez-Abreu D, López-Castro R, Guirado M, Camps C, Bosch-Barrera J, García-Campelo R, Ortega-Granados AL, González-Larriba JL, Casal-Rubio J, Domine M, Massutí B, Sala MÁ, Bernabé R, Oramas J, Del Barco E. Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study). Transl lung cancer Res. 2019 Aug;8(4):461–75. PMID: 31555519. DOI: 10.21037/tlcr.2019.08.05. http://www.ncbi.nlm.nih.gov/pubmed/31555519
Enlace

Rivera F, Romero C, Jimenez-Fonseca P, Izquierdo-Manuel M, Salud A, Martínez E, Jorge M, Arrazubi V, Méndez JC, García-Alfonso P, Reboredo M, Barriuso J, Muñoz-Unceta N, Jimeno R, López C. Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial. Cancer Chemother Pharmacol. Springer Berlin Heidelberg; 2019;83(6):1175–81. PMID: 30927036. DOI: 10.1007/s00280-019-03820-7. http://www.ncbi.nlm.nih.gov/pubmed/30927036
Enlace

Rubio C, Martínez-Fernández M, Segovia C, Lodewijk I, Suarez-Cabrera C, Segrelles C, López-Calderón F, Munera-Maravilla E, Santos M, Bernardini A, García-Escudero R, Lorz C, Gómez-Rodriguez MJ, de Velasco G, Otero I, Villacampa F, Guerrero-Ramos F, Ruiz S, de la Rosa F, Domínguez-Rodríguez S, Real FX, Malats N, Castellano D, Dueñas M, Paramio JM. CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status. Clin Cancer Res. 2019;25(1):390–402. PMID: 30242024. DOI: 10.1158/1078-0432.CCR-18-0685. http://www.ncbi.nlm.nih.gov/pubmed/30242024
Enlace

Ruiz-Banobre J, Areses-Manrique MC, Mosquera-Martinez J, Cortegoso A,Afonso-Afonso FJ, de Dios-Alvarez N, Fernandez-Nunez N, Azpitarte-Raposeiras C,Amenedo M, Santome L, Firvida-Perez JL, Garcia-Campelo R, Garcia-Gonzalez J,Casal-Rubio J, Vazquez S. Evaluation of the lung immune prognostic index inadvanced non-small cell lung cancer patients under nivolumab monotherapy. TranslLung Cancer Res. 2019 Dec;8(6):1078-1085. doi: 10.21037/tlcr.2019.11.07. PubMedPMID: 32010585; PubMed Central PMCID: PMC6976357.
Enlace

Santaballa A, De Castro J, Maurel J, Lázaro M, Vera R, Alba E. Optimization of oral chemotherapy in outpatient clinics in Spain: results from a survey of the Spanish Society of Medical Oncology (SEOM). Clin Transl Oncol. 2019 Apr;21(4):534–8. PMID: 30327937. DOI: 10.1007/s12094-018-1951-z. http://www.ncbi.nlm.nih.gov/pubmed/30327937
Enlace

Segovia C, San José-Enériz E, Munera-Maravilla E, Martínez-Fernández M, Garate L, Miranda E, Vilas-Zornoza A, Lodewijk I, Rubio C, Segrelles C, Valcárcel LV, Rabal O, Casares N, Bernardini A, Suarez-Cabrera C, López-Calderón FF, Fortes P, Casado JA, Dueñas M, Villacampa F, Lasarte JJ, Guerrero-Ramos F, de Velasco G, Oyarzabal J, Castellano D, Agirre X, Prósper F, Paramio JM. Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression. Nat Med. 2019;25(7):1073–81. PMID: 31270502. DOI: 10.1038/s41591-019-0499-y. http://www.ncbi.nlm.nih.gov/pubmed/31270502
Enlace

Isabel Lorenzo Lorenzo, Paula González Villarroel, Isaura Fernández Pérez. Prevención farmacológica del cáncer de predisposición hereditaria. Cáncer Hereditario, 3ª edición, páginas 421-441. Sociedad Española de Oncología Médica.(SEOM) 2019; ISBN: 978-84-09-10462-8.
Enlace

Campos Balea B, Fernández Bouza E, Barbagelata López C, Brozos Vázquez EM, CAROU FRIEIRO, IRIA; Fernández Pérez I, Iglesias Rey L, Quindós Varela M, Carmona Campos M, Antolín Novoa S. Guía gallega de manejo de la trombosis asociada a cáncer. Rivera Gallego A, Lopez-Lopez R (eds.). Barcelona: Bubblegum Communication Services; 2019. Con el Aval de la Sociedad Oncológica de Galicia (. ISBN: 978-84-09-1419-4. https://runa.sergas.es/xmlui/handle/20.500.11940/12881
Enlace

Areses Manrique MC, Mosquera Martínez J, García González J, Afonso Afonso FJ, Lázaro Quintela M, Fernández Núñez N, Azpitarte Raposeiras C, Amenedo Gancedo M, Santomé Couto L, García Campelo MR, Muñoz Iglesias J, Cortegoso Mosquera A, Vilchez Simo R, Casal Rubio J, Campos Balea B, Carou Frieiro I, Alonso-Jaudenes Curbera G, Anido Herranz U, García Mata J, Fírvida Pérez JL. Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience. Transl lung cancer Res. 2018 Jun;7(3):404–15. PMID: 30050778. DOI: 10.21037/tlcr.2018.04.03. http://www.ncbi.nlm.nih.gov/pubmed/30050778
Enlace

Cassinello J, Arranz JÁ, Piulats JM, Sánchez A, Pérez-Valderrama B, Mellado B, Climent MÁ, Olmos D, Carles J, Lázaro M. SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017). Clin Transl Oncol. 2018 Jan;20(1):57–68. PMID: 29134562. DOI: 10.1007/s12094-017-1783-2. http://www.ncbi.nlm.nih.gov/pubmed/29134562
Enlace

Costa Rivas M, Huidobro Vence G, Fírvida Pérez JL, Campos Balea B, García Gonzalez J, Lázaro Quintela M, Caeiro Muñoz M, Taboada Valladares B, Castro Gómez JE, Vázquez Estevez S, Afonso Afonso FJ, Azpitarte Raposeiras C, Amenedo Gancedo M, Casal Rubio J. Concurrent chemoradiation for locally advanced stage III non-small cell lung cancer with cisplatin, vinorelbine, and thoracic radiotherapy: a phase II study from the Galician Lung Cancer Group. Clin Transl Oncol. 2018 Nov;20(11):1467–73. PMID: 29696478. DOI: 10.1007/s12094-018-1880-x. http://www.ncbi.nlm.nih.gov/pubmed/29696478
Enlace

Fernández A, Salgado M, García A, Buxò E, Vera R, Adeva J, Jiménez-Fonseca P, Quintero G, Llorca C, Cañabate M, López LJ, Muñoz A, Ramírez P, González P, López C, Reboredo M, Gallardo E, Sanchez-Cánovas M, Gallego J, Guillén C, Ruiz-Miravet N, Navarro-Pérez V, De la Cámara J, Alés-Díaz I, Pazo-Cid RA, Carmona-Bayonas A. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study. BMC Cancer. BMC Cancer; 2018 Nov;18(1):1185. PMID: 30497432. DOI: 10.1186/s12885-018-5101-3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267080/pdf/12885_2018_Article_5101.pdf
Enlace

Losa F, Soler G, Casado A, Estival A, Fernández I, Giménez S, Longo F, Pazo-Cid R, Salgado J, Seguí MÁ. SEOM clinical guideline on unknown primary cancer (2017). Clin Transl Oncol. 2018 Jan;20(1):89–96. PMID: 29230692. DOI: 10.1007/s12094-017-1807-y. http://www.ncbi.nlm.nih.gov/pubmed/29230692
Enlace

Paumard-Hernández B, Calvete O, Inglada Pérez L, Tejero H, Al-Shahrour F, Pita G, Barroso A, Carlos Triviño J, Urioste M, Valverde C, González Billalabeitia E, Quiroga V, Francisco Rodríguez Moreno J, Fernández Aramburo A, López C, Maroto P, Sastre J, José Juan Fita M, Duran I, Lorenzo-Lorenzo I, Iranzo P, García Del Muro X, Ros S, Zambrana F, María Autran A, Benítez J. Whole exome sequencing identifies PLEC, EXO5 and DNAH7 as novel susceptibility genes in testicular cancer. Int J cancer. 2018 May;143(8):1954–62. PMID: 29761480. DOI: 10.1002/ijc.31604. http://www.ncbi.nlm.nih.gov/pubmed/29761480
Enlace

Ruiz-Llorente L, Contreras-Jurado C, Martínez-Fernández M, Paramio JM, Aranda A. Thyroid Hormone Receptors Regulate the Expression of microRNAs with Key Roles in Skin Homeostasis. Thyroid. 2018;28(7):921–32. PMID: 29742977. DOI: 10.1089/thy.2017.0369. http://www.ncbi.nlm.nih.gov/pubmed/29742977
Enlace

Sabell Pérez-Salgado F, Vázquez-Estévez S, Anido-Herranz U, Blanco-Parra M, Casas-Nebra FJ, Fernández-Calvo O, Lázaro-Quintela M, López-García S. Approach of the patient with renal cancer: Is there a collaboration between urology and oncology? Actas Urol Esp. 2018 Jan;42(1):1–4. PMID: 28587846. DOI: 10.1016/j.acuro.2017.04.001. http://www.ncbi.nlm.nih.gov/pubmed/28587846
Enlace

Suárez-Cabrera C, de la Peña B, González LL, Page A, Martínez-Fernández M, Casanova ML, Paramio JM, Rojo-Sebastián A, Moreno-Bueno G, Maroto A, Ramírez Á, Navarro M. The Ras-related gene ERAS is involved in human and murine breast cancer. Sci Rep. 2018;8(1):13038. PMID: 30158566. DOI: 10.1038/s41598-018-31326-4. http://www.ncbi.nlm.nih.gov/pubmed/30158566
Enlace

Areses M, Campelo RG, García González J, Afonso FJ, Lazaro ME, Campos B, Azpitarte C, Amenedo M, Santomé L, Ron DA, Alonso-Jaudenes G, Baron F, Vilchez R, Casal J, Fernandez N, Carou I, Mosquera J, Anido U, Garcia Mata J, Firvida J. The real-world experience with nivolumab in previously treated patients with advanced non small cell lung cancer (NSCLC): A Galician Lung Cancer Group clinical practice. J Clin Oncol. 2017 May;35(15_suppl):e20564. DOI: 10.1200/JCO.2017.35.15_suppl.e20564. IF2017: 26.360; D1. http://ascopubs.org/doi/10.1200/JCO.2017.35.15_suppl.e20564
Enlace

Barnes TA, Amir E, Templeton AJ, Gomez-Garcia S, Navarro B, Seruga B, Ocana A. Efficacy, safety, tolerability and price of newly approved drugs in solid tumors. Cancer Treat Rev. 2017 May;56:1–7. PMID: 28437678. DOI: 10.1016/j.ctrv.2017.03.011. IF2017: 8.122; D1. http://www.ncbi.nlm.nih.gov/pubmed/28437678
Enlace

Cameselle-Teijeiro JF, Valdés-Pons J, Cameselle-Cortizo L, Fernández-Pérez I, Lamas-González MJ, Iglesias-Faustino S, Alonso-Figueirido E, Cortizo-Torres M-E, Agras-Suárez M-C, Iglesias-Salgado A, Salgado-Costas M, Friande-Pereira S, Schmitt FC. Tumours of the Uterine Corpus: A Histopathological and Prognostic Evaluation Preliminary of 429 Patients. J Clin Med Exp Images. 2017;1(1):011–9. DOI: 10.29328/journal.jcmei.1001004. IF2017: N/A. https://www.heighpubs.org/jcmei/jcmei-aid1004.php
Enlace

De Castro J, González-Larriba JL, Vázquez S, Massutí B, Sanchez-Torres JM, Dómine M, Garrido P, Calles A, Artal A, Collado R, García R, Sereno M, Majem M, Macías JA, Juan O, Gómez-Codina J, Hernández B, Lázaro M, Ortega AL, Cobo M, Trigo JM, Carcereny E, Rolfo C, Macia S, Muñoz J, Diz P, Méndez M, Rosillo F, Paz-Ares L, Cardona J V, Isla D. Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy. Clin Transl Oncol. 2017 Feb;19(2):219–26. PMID: 27371031. DOI: 10.1007/s12094-016-1527-8. IF2017: 2.392; Q3. http://www.ncbi.nlm.nih.gov/pubmed/27371031
Enlace

Feber A, Dhami P, Dong L, de Winter P, Tan WS, Martínez-Fernández M, Paul DS, Hynes-Allen A, Rezaee S, Gurung P, Rodney S, Mehmood A, Villacampa F, de la Rosa F, Jameson C, Cheng KK, Zeegers MP, Bryan RT, James ND, Paramio JM, Freeman A, Beck S, Kelly JD. UroMark-a urinary biomarker assay for the detection of bladder cancer. Clin Epigenetics. 2017;9:8. PMID: 28163793. DOI: 10.1186/s13148-016-0303-5. http://www.ncbi.nlm.nih.gov/pubmed/28163793
Enlace

Gomez Garcia S, Costa Rivas M, Areses Manrique MC, Fernández Núñez N, Garcia J, Caeiro M, Castro E, Formoso I, Calvo P, De Dios Alvarez N, Firvida J, Campos B, Azpitarte C, Afonso FJ, Amenedo M, Casal Rubio J. Concurrent chemoradiation (CChRT) for locally advanced stage III non-small cell lung cancer (NSCLC) with cisplatin and vinorelbine and thoracic radiotherapy: A phase II study from the Galician Lung Cancer Group. J Clin Oncol. 2017 May;35(15_suppl):e20067. DOI: 10.1200/JCO.2017.35.15_suppl.e20067. IF2017: 26.360; D1. http://ascopubs.org/doi/10.1200/JCO.2017.35.15_suppl.e20067
Enlace

González Del Alba A, Arranz JÁ, Puente J, Méndez-Vidal MJ, Gallardo E, Grande E, Pérez-Valderrama B, González-Billalabeitia E, Lázaro-Quintela M, Pinto Á, Lainez N, Piulats JM, Esteban E, Maroto Rey JP, García JA, Suárez C. Recent advances in genitourinary tumors: A review focused on biology and systemic treatment. Crit Rev Oncol Hematol. 2017 May;113:171–90. PMID: 28427506. DOI: 10.1016/j.critrevonc.2017.03.010. IF2017: 4.495; Q1. http://www.ncbi.nlm.nih.gov/pubmed/28427506
Enlace

González-Larriba JL, Lázaro-Quintela M, Cobo M, Dómine M, Majem M, García-Campelo R. Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis. Transl lung cancer Res. 2017 Dec;6(Suppl 1):S21–34. PMID: 29299405. DOI: 10.21037/tlcr.2017.10.03. IF2017: N/A. http://www.ncbi.nlm.nih.gov/pubmed/29299405
Enlace

Lorenzo-Lorenzo I, Fernández-Pérez I, Alonso-Herrero A, Villanueva-Sil MJ. Breast Cancer Chemoprevention: What and When? Cancer Chemother Rev. 2017;12(2):46–57. IF2017: N/A. http://www.cancerchemotherapyreviews.com/resumen.asp?id=860&indice=2017122
Enlace

Martin Jimenez M, Calvo Ferrandiz A, Aparicio Urtasun J, Garcia-Campelo R, Gonzalez-Flores E, Lazaro Quintela M, Muñoz Mateu M, Rodriguez Sanchez CA, Santaballa Bertran A, Sepulveda Sanchez JM, Vera Garcia R, Virizuela Echaburu JA, Segui Palmer MA. New clinical trials regulation in Spain: analysis of royal decree 1090/2015. Clin Transl Oncol. 2017 Mar;19(3):291–300. PMID: 27718157. DOI: 10.1007/s12094-016-1550-9. IF2017: 2.392; Q3. http://www.ncbi.nlm.nih.gov/pubmed/27718157
Enlace

Martínez VG, Rubio C, Martínez-Fernández M, Segovia C, López-Calderón F, Garín MI, Teijeira A, Munera-Maravilla E, Varas A, Sacedón R, Guerrero F, Villacampa F, de la Rosa F, Castellano D, López-Collazo E, Paramio JM, Vicente Á, Dueñas M. BMP4 Induces M2 Macrophage Polarization and Favors Tumor Progression in Bladder Cancer. Clin Cancer Res. 2017 Dec;23(23):7388–99. PMID: 28928159. DOI: 10.1158/1078-0432.CCR-17-1004. http://www.ncbi.nlm.nih.gov/pubmed/28928159
Enlace

Méndez Méndez JC, Ramos M, De la Cámara Gómez JC, Pellón ML, Covela M, Quintero Aldana GA, Salgado Fernandez M, Fernández-Montes A, Reboredo M, Valladares-Ayerbes M, Jorge Fernandez M, González Villarroel P, Romero Reinoso C. 553P – First-line panitumumab (P) plus capecitabine (C) for the treatment of elderly patients (pts) with wild-type KRAS metastatic colorectal cancer (mCRC): Preliminary results of the phase II, PANEL GITuD-2011-01 study. Ann Oncol. 2017 Sep;28(suppl_5):553P. DOI: 10.1093/annonc/mdx393.079. IF2017: 13.930; D1. http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx393.079/4109851/553PFirstline-panitumumab-P-plus-capecitabine-C
Enlace

Ocana Fernandez A, Ruiz Borrego M, Gil Martin M, Antolin S, Atienza M, Montaño A, Ribelles N, Guerrero A, Muñoz M, Fernández-Pérez I, Urruticoechea A, Falcon Gonzalez A, Pernas Simon S, Prato Varela J, Escudero MJ, Benito S, Caballero R, Carrasco E, Rojo F, Pandiella A. 239PD – A phase II trial of dasatinib (D) in combination with trastuzumab (T) and paclitaxel (P) in the first line treatment of HER2 positive metastatic breast cancer (MBC) patients (pts): GEICAM/2010-04. Ann Oncol. 2017 Sep;28(suppl_5):239PD. DOI: 10.1093/annonc/mdx365.002. IF2017: 13.930; D1; JCR-CAT: ONCOLOGY. http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx365.002/4108468/239PDA-phase-II-trial-of-dasatinib-D-in
Enlace

Perez-Segura P, Palacio JE, Vazquez L, Monereo S, de Las Penas R, de Icaya PMM, Gravalos C, Lecube A, Blasco A, Garcia-Almeida JM, Barneto I, Goday A, Pérez-Segura P, Palacio JE, Vázquez L, Monereo S, de Las Peñas R, de Icaya PMM, Grávalos C, Lecube A, Blasco A, García-Almeida JM, Barneto I, Goday A. Peculiarities of the obese patient with cancer: a national consensus statement by the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2017 Jun;19(6):682–94. PMID: 28074400. DOI: 10.1007/s12094-016-1601-2. IF2017: 2.392; Q3. http://www.ncbi.nlm.nih.gov/pubmed/28074400
Enlace

Puente J, Laínez N, Dueñas M, Méndez-Vidal MJ, Esteban E, Castellano D, Martinez-Fernández M, Basterretxea L, Juan-Fita MJ, Antón L, León L, Lambea J, Pérez-Valderrama B, Vázquez S, Suarez C, Del Muro XG, Gallardo E, Maroto JP, Samaniego ML, Suárez-Paniagua B, Sanz J, Paramio JM, SOGUG (Spanish Oncology Genitourinary Group). Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma. Oncotarget. 2017 May;8(18):30410–21. PMID: 28423742. DOI: 10.18632/oncotarget.16494. http://www.ncbi.nlm.nih.gov/pubmed/28423742
Enlace

Segovia C, Martínez-Fernández M, Dueñas M, Rubio C, López-Calderón FF, Costa C, Saiz-Ladera C, Fernández-Grajera M, Duarte J, Muñoz HG, de la Rosa F, Villacampa F, Castellano D, Paramio JM. Opposing roles of PIK3CA gene alterations to EZH2 signaling in non-muscle invasive bladder cancer. Oncotarget. 2017 Feb;8(6):10531–42. PMID: 28060766. DOI: 10.18632/oncotarget.14453. http://www.ncbi.nlm.nih.gov/pubmed/28060766
Enlace

Segovia C, Paramio JM, Martínez-Fernández M. Epigenetic mutations and cancer therapy Effectiven(EZH2). Transl Cancer Res. 2017 May;6(S3):S629–34. DOI: 10.21037/tcr.2017.05.27. http://doi.org/10.21037/tcr.2017.05.27
Enlace

Vera R, Gómez M, Ayuso JR, Figueras J, Garcia-Alfonso P, Martinez V, Lacasta A, Ruiz A, Safont MJ, Aparicio J, Campos J, Cámara J, Martin M, Montagut C, Pericay C, Viéitez JM, Falcó E, Jorge M, Marín Vera M, Salgado Fernandez M. 590P – Correlation between RECIST-criteria, morphologic response by CT and pathologic regression in hepatic metastasis secondary to colorectal cancer: The AVAMET study. Ann Oncol. 2017 Sep;28(suppl_5):590P. DOI: 10.1093/annonc/mdx393.115. IF2017: 13.930; D1. http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx393.115/4109887/590PCorrelation-between-RECISTcriteria-morphologic
Enlace

Fernández-Pérez I, Alonso-Herrero A, Gómez-García S, Costa-Rivas M. Enfermedad Tromboembólica Venosa y Cáncer de Ovario. Oncology Thrombosis Risk. Esmon Publicidad; 2017. ISBN: 9788494660511. https://books.google.es/books/about/Enfermedad_tromboembólica_venosa_y_cán.html?id=UwrNwQEACAAJ&redir_esc=y
Enlace

Álvarez López J, Fernández-Calvo O, Charín Pato G. Fisterra Guías Clínicas: Melanoma cutáneo. 2017. https://www.fisterra.com/guias-clinicas/melanoma-cutaneo/#27021
Enlace

Fírvida-Pérez JL, Arias-Ron D, Fernández-Calvo O. Fisterra Guías Clínicas: Cáncer de pulmón. 2017. https://www.fisterra.com/guias-clinicas/cancer-pulmon/#26990
Enlace

Lamelo-Alfonsín F, Charlín-Pato G, Fernandez-Calvo O. Fisterra Guías Clínicas: Efectos secundarios del tratamiento oncológico. 2017. https://www.fisterra.com/guias-clinicas/efectos-secundarios-tratamiento-oncologico/#26976
Enlace

Balana C, De Las Penas R, Sepúlveda JM, Gil-Gil MJ, Luque R, Gallego O, Carrato C, Sanz C, Reynes G, Herrero A, Ramirez JL, Pérez-Segura P, Berrocal A, Vieitez JM, Garcia A, Vazquez-Estevez S, Peralta S, Fernández-Pérez I, Henriquez I, Martinez-Garcia M, De la Cruz JJ, Capellades J, Giner P, Villà S. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial. J Neurooncol. 2016 May;127(3):569–79. PMID: 26847813. DOI: 10.1007/s11060-016-2065-5. IF2016: 2.980; Q2. http://www.ncbi.nlm.nih.gov/pubmed/26847813
Enlace

Cameselle-Teijeiro JF, Cameselle-Cortizo L, Valdés-Pons J, Fernández-Pérez I, Lamas-González M, Iglesias-Faustino S, Figueiredo-Alonso E, Cortizo-Torres M, Iglesias-Salgado A, Salgado-Costas M, Schmitt F. Breast Cancer and Ovarian Cancer in Monozygotic Twins. Clin Oncol. 2016;1:1016. IF2016: N/A. https://adicam.net/files/DOC-20160729-WA0012.pdf
Enlace

Costa C, Santos M, Martínez-Fernández M, Lorz C, Lázaro S, Paramio JM. Deregulation of the pRb-E2F4 axis alters epidermal homeostasis and favors tumor development. Oncotarget. 2016;7(46):75712–28. PMID: 27708231. DOI: 10.18632/oncotarget.12362. http://www.ncbi.nlm.nih.gov/pubmed/27708231
Enlace

Estévez SV, Herranz UA, Calvo OF, Afonso Afonso FJ, Couto LS, Lázaro-Quintela M, Mateos LL, Maciá Escalante S. Prostate cancer perspectives after chaarted: Optimizing treatment sequence. Crit Rev Oncol Hematol. Elsevier Ireland Ltd; 2016 Nov;107:119–27. PMID: 27823639. DOI: 10.1016/j.critrevonc.2016.08.007. IF2016: 4.491; Q1. http://www.ncbi.nlm.nih.gov/pubmed/27823639
Enlace

Fonseca PJ, Carmona-Bayonas A, García IM, Marcos R, Castañón E, Antonio M, Font C, Biosca M, Blasco A, Lozano R, Ramchandani A, Beato C, de Castro EM, Espinosa J, Martínez-García J, Ghanem I, Cubero JH, Manrique IA, Navalón FG, Sevillano E, Manzano A, Virizuela J, Garrido M, Mondéjar R, Arcusa MÁ, Bonilla Y, Pérez Q, Gallardo E, del Carmen Soriano M, Cardona M, Lasheras FS, Cruz JJ, Ayala F, Spanish Soc Med Oncology SEOM, FINITE Investigators. A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia. Br J Cancer. 2016 May;114(11):1191–8. PMID: 27187687. DOI: 10.1038/bjc.2016.118. IF2016: 6.176; Q1. http://www.ncbi.nlm.nih.gov/pubmed/27187687
Enlace

García J, Santomé L, Anido U, Fernández-Calvo O, Afonso-Afonso J, Lázaro M, Medina A, Vázquez Estévez S. Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU). Curr Oncol Rep. 2016 Dec;18(12):72. PMID: 27812861. DOI: 10.1007/s11912-016-0556-3. IF2016: 2.608; Q3. http://www.ncbi.nlm.nih.gov/pubmed/27812861
Enlace

Gómez García S, Clemons M, Amir E. Rethinking end-points for bone-targeted therapy in advanced cancer. Eur J Cancer. 2016 Aug;63:105–9. PMID: 27299662. DOI: 10.1016/j.ejca.2016.05.014. IF2016: 6.029; Q1. http://www.ncbi.nlm.nih.gov/pubmed/27299662
Enlace

Lainez N, García-Donas J, Esteban E, Puente J, Sáez MI, Gallardo E, Pinto-Marín Á, Vázquez-Estévez S, León L, García-Carbonero I, Suárez-Rodríguez C, Molins C, Climent-Duran MA, Lázaro-Quintela M, González Del Alba A, Méndez-Vidal MJ, Chirivella I, Afonso FJ, López-Brea M, Sala-González N, Domenech M, Basterretxea L, Santander-Lobera C, Gil-Arnáiz I, Fernández O, Caballero-Díaz C, Mellado B, Marrupe D, García-Sánchez J, Sánchez-Escribano R, Fernández Parra E, Villa Guzmán JC, Martínez-Ortega E, Belén González M, Morán M, Suarez-Paniagua B, Lecumberri MJ, Castellano D. Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study. BMC Cancer. 2016 Feb;16(1):135. PMID: 26906039. DOI: 10.1186/s12885-016-2084-9. IF2016: 3.288; Q2. http://www.ncbi.nlm.nih.gov/pubmed/26906039
Enlace

Lázaro M, Gallardo E, Doménech M, Pinto Á, Del Alba AG, Puente J, Fernández O, Font A, Lainez N, Vázquez S. SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016). Clin Transl Oncol. 2016 Dec;18(12):1197–205. PMID: 27900539. DOI: 10.1007/s12094-016-1584-z. IF2016: 2.353; Q3. http://www.ncbi.nlm.nih.gov/pubmed/27900539
Enlace

López-Pousa A, Martin Broto J, Martinez Trufero J, Sevilla I, Valverde C, Alvarez R, Carrasco Alvarez JA, Cruz Jurado J, Hindi N, Garcia Del Muro X. SEOM Clinical Guideline of management of soft-tissue sarcoma (2016). Clin Transl Oncol. 2016 Dec;18(12):1213–20. PMID: 27905051. DOI: 10.1007/s12094-016-1574-1. IF2016: 2.353; Q3. http://www.ncbi.nlm.nih.gov/pubmed/27905051
Enlace

Martínez-Fernández M, Paramio JM, Dueñas M. RNA Detection in Urine: From RNA Extraction to Good Normalizer Molecules. J Mol Diagn. 2016 Jan;18(1):15–22. PMID: 26586227. DOI: 10.1016/j.jmoldx.2015.07.008. http://www.ncbi.nlm.nih.gov/pubmed/26586227
Enlace

Martínez-Jañez N, Chacón I, de Juan A, Cruz-Merino L, Del Barco S, Fernández I, García-Teijido P, Gómez-Bernal A, Plazaola A, Ponce J, Servitja S, Zamora P. Anti-HER2 Therapy Beyond Second-Line for HER2-Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel. Breast Care (Basel). 2016 Apr;11(2):133–8. PMID: 27239176. DOI: 10.1159/000443601. IF2016: 1.553; Q3. http://www.ncbi.nlm.nih.gov/pubmed/27239176
Enlace

Pena C, Alvarez M, Fernández Núñez N, Alonso Herrero A, Amenedo M, Firvida Perez JL, Campos Balea BÂ, Gomez Garcia S, Covela Rúa M, Costa Rivas M, Cadavid Vieitez L, Vazquez-Estevez S. ERCC1 expression in tumor tissue as biomarker of outcomes of oral vinorelbine-cisplatin (oVP) combination in metastatic squamous cell lung cancer (SqLC): A prospective study—GGCP 052/12. J Clin Oncol. 2016 May;34(15_suppl):e20533. DOI: 10.1200/JCO.2016.34.15_suppl.e20533. http://ascopubs.org/doi/10.1200/JCO.2016.34.15_suppl.e20533
Enlace

Pérez-Segura P, Manneh R, Ceballos I, García A, Benavides M, Fuster J, Vaz MA, Cano JM, Berros JP, Covela M, Moreno V, Quintanar T, García Bueno JM, Fernández I, Sepúlveda J. GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status. Clin Transl Oncol. 2016 Aug;18(8):805–12. PMID: 26542177. DOI: 10.1007/s12094-015-1444-2. IF2016: 2.353; Q3. http://www.ncbi.nlm.nih.gov/pubmed/26542177
Enlace

Pérez-Valderrama B, Arranz Arija JA, Rodríguez Sánchez A, Pinto Marín A, Borrega García P, Castellano Gaunas DE, Rubio Romero G, Maximiano Alonso C, Villa Guzmán JC, Puertas Álvarez JL, Chirivella González I, Méndez Vidal MJ, Juan Fita MJ, León-Mateos L, Lázaro Quintela M, García Domínguez R, Jurado García JM, Vélez de Mendizábal E, Lambea Sorrosal JJ, García Carbonero I, González del Alba A, Suárez Rodríguez C, Jiménez Gallego P, Meana García JA, García Marrero RD, Gajate Borau P, Santander Lobera C, Molins Palau C, López Brea M, Fernández Parra EM, Reig Torras O, Basterretxea Badiola L, Vázquez Estévez S, González Larriba JL. Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study. Ann Oncol Off J Eur Soc Med Oncol. 2016 Apr;27(4):706–11. PMID: 26658889. DOI: 10.1093/annonc/mdv601. IF2016: 11.855; D1. http://www.ncbi.nlm.nih.gov/pubmed/26
Enlace

Sánchez-Ares M, Cameselle-Teijeiro JM, Vázquez-Estévez S, Lázaro-Quintela M, Vázquez-Boquete Á, Afonso-Afonso FJ, Casal-Rubio J, González-Piñeiro AL, Rico-Rodríguez Y, Fírvida-Pérez JL, Ruíz-Bañobre J, Couso E, Santomé L, Pérez-Becerra R, García-Campelo R, Amenedo M, Azpitarte-Raposeiras C, Antúnez J, Abdulkader I. Fluorescence in situ hybridization analysis of the ALK gene in 2,045 non-small cell lung cancer patients from North-Western Spain (Galicia). Oncol Lett. 2016 Aug;12(2):1403–7. PMID: 27446444. DOI: 10.3892/ol.2016.4788. IF2016: 1.390; Q4. http://www.ncbi.nlm.nih.gov/pubmed/27446444
Enlace

Vázquez S, Casal J, Afonso Afonso FJ, Fírvida JL, Santomé L, Barón F, Lázaro M, Pena C, Amenedo M, Abdulkader I, González-Arenas C, Fachal L, Vega A. EGFR testing and clinical management of advanced NSCLC: a Galician Lung Cancer Group study (GGCP 048-10). Cancer Manag Res. 2016 Feb;8:11–20. PMID: 26893581. DOI: 10.2147/CMAR.S85173. IF2016: 3.851; Q2. http://www.ncbi.nlm.nih.gov/pubmed/26893581
Enlace

Lorenzo-Lorenzo I. TNE torácicos: pulmón y timo. Guía práctica de diagnóstico, tratamiento y seguimiento de tumores neuroendocrinos. Versión 3. EdikaMed S.L; 2016. p. 51–70. ISBN: 978-84-7877-892-8. http://www.getne.org/LinkClick.aspx?fileticket=lxEtmyHm2NI%3D
Enlace

Lázaro-Quintela M, Vázquez-Éstevez S, León-Mateos L, Grande-Pulido E, Antón-Aparicio L. Tratado de tumores raros. Grupo GETHI; 2016. ISBN: 978-84-697-0596-4. http://www.tratadodetumoresraros.com/
Enlace

Anido Herranz U, Fernández Calvo O, Afonso Afonso FJ, Rodríguez Martínez de Llano S, Lázaro Quintela M, León Mateos L, Vázquez Estévez S, Antón Aparicio LM. Radium-223 dichloride: a new paradigm in the treatment of prostate cancer. Expert Rev Anticancer Ther. 2015 Mar;15(3):339–48. PMID: 25555355. DOI: 10.1586/14737140.2015.999045. IF2015: 2.094; Q3. http://www.ncbi.nlm.nih.gov/pubmed/25555355
Enlace

Carmona-Bayonas A, Jiménez-Fonseca P, Virizuela Echaburu J, Antonio M, Font C, Biosca M, Ramchandani A, Martínez J, Hernando Cubero J, Espinosa J, Martínez de Castro E, Ghanem I, Beato C, Blasco A, Garrido M, Bonilla Y, Mondéjar R, Arcusa Lanza MÁ, Aragón Manrique I, Manzano A, Sevillano E, Castañón E, Cardona M, Gallardo Martín E, Pérez Armillas Q, Sánchez Lasheras F, Ayala de la Peña F. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study. J Clin Oncol. 2015 Feb;33(5):465–71. PMID: 25559804. DOI: 10.1200/JCO.2014.57.2347. IF2015: 20.982; D1. http://www.ncbi.nlm.nih.gov/pubmed/25559804
Enlace

Goday A, Barneto I, García-Almeida JM, Blasco A, Lecube A, Grávalos C, Martínez de Icaya P, de las Peñas R, Monereo S, Vázquez L, Palacio JE, Pérez-Segura P. Obesity as a risk factor in cancer: A national consensus of the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2015 Oct;17(10):763–71. PMID: 26036853. DOI: 10.1007/s12094-015-1306-y. http://www.ncbi.nlm.nih.gov/pubmed/26036853
Enlace

Iglesias Rey L, Fernández Pérez I, Barbagelata López C, Rivera Gallego A. [Venous thrombosis associated with central venous catheter use in patients with cancer]. Med Clin (Barc). 2015 Jan;144 Suppl(Suppl 1):41–3. PMID: 25771092. DOI: 10.1016/S0025-7753(15)30018-X. IF2015: 1.267; Q2. http://www.ncbi.nlm.nih.gov/pubmed/25771092
Enlace

Maraver A, Fernandez-Marcos PJ, Cash TP, Mendez-Pertuz M, Dueñas M, Maietta P, Martinelli P, Muñoz-Martin M, Martínez-Fernández M, Cañamero M, Roncador G, Martinez-Torrecuadrada JL, Grivas D, de la Pompa JL, Valencia A, Paramio JM, Real FX, Serrano M. NOTCH pathway inactivation promotes bladder cancer progression. J Clin Invest. 2015 Feb;125(2):824–30. PMID: 25574842. DOI: 10.1172/JCI78185. http://www.ncbi.nlm.nih.gov/pubmed/25574842
Enlace

Martínez-Fernández M, Dueñas M, Feber A, Segovia C, García-Escudero R, Rubio C, López-Calderón FF, Díaz-García C, Villacampa F, Duarte J, Gómez-Rodriguez MJ, Castellano D, Rodriguez-Peralto JL, de la Rosa F, Beck S, Paramio JM. A Polycomb-mir200 loop regulates clinical outcome in bladder cancer. Oncotarget. 2015 Dec;6(39):42258–75. PMID: 26517683. DOI: 10.18632/oncotarget.5546. http://www.ncbi.nlm.nih.gov/pubmed/26517683
Enlace

Martínez-Fernández M, Feber A, Dueñas M, Segovia C, Rubio C, Fernandez M, Villacampa F, Duarte J, López-Calderón FF, Gómez-Rodriguez MJ, Castellano D, Rodriguez-Peralto JL, de la Rosa F, Beck S, Paramio JM. Analysis of the Polycomb-related lncRNAs HOTAIR and ANRIL in bladder cancer. Clin Epigenetics. 2015;7:109. PMID: 26457124. DOI: 10.1186/s13148-015-0141-x. http://www.ncbi.nlm.nih.gov/pubmed/26457124
Enlace

Martínez-Fernández M, Rubio C, Segovia C, López-Calderón FF, Dueñas M, Paramio JM. EZH2 in Bladder Cancer, a Promising Therapeutic Target. Int J Mol Sci. 2015 Nov;16(11):27107–32. PMID: 26580594. DOI: 10.3390/ijms161126000. http://www.ncbi.nlm.nih.gov/pubmed/26580594
Enlace

Quintela ML, Mateos LL, Estévez SV, Calvo OF, Herranz UA, Afonso FJA, Santomé L, Aparicio LA. Enzalutamide: a new prostate cancer targeted therapy against the androgen receptor. Cancer Treat Rev. 2015 Mar;41(3):247–53. PMID: 25638257. DOI: 10.1016/j.ctrv.2014.12.006. IF2015: 7.983; D1. http://www.ncbi.nlm.nih.gov/pubmed/25638257
Enlace

Quintero-Aldana G, Jorge M, Grande C, Salgado-Fernández M, Gallardo E, Varela S, López C, Villanueva MJ, Fernández A, Alvarez E, González P, Castellanos J, Casal J, López R, Campos Balea B. Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer. Cancer Chemother Pharmacol. 2015 Oct;76(4):731–7. PMID: 26242221. DOI: 10.1007/s00280-015-2839-z. IF2015: 2.824; Q2. http://www.ncbi.nlm.nih.gov/pubmed/26242221
Enlace

Salvador J, Manso L, de la Haba J, Jaen A, Ciruelos E, de Villena MC, Gil M, Murias A, Galan A, Jara C, Bayo J, Baena JM, Casal J, Mel JR, Blancas I, Sanchez Rvira P. Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Clin Transl Oncol. 2015 Feb;17(2):160–6. PMID: 25119930. DOI: 10.1007/s12094-014-1210-x. IF2015: 2.075; Q3. http://www.ncbi.nlm.nih.gov/pubmed/25119930
Enlace

Vázquez S, Villanueva M, Fírvida J, Campos B, Lázaro M, Huidobro G, Areses M del, Fernández N, Covela M, Casal J. Erlotinib as Second-Line Therapy for Patients with Advanced Non-Small-Cell Lung Cancer and Wild-Type EGFR Tumors. J Anal Oncol. 2015 Sep;4(3):94–101. DOI: 10.6000/1927-7229.2015.04.03.1. IF2015: N/A. http://www.lifescienceglobal.com/journals/journal-of-analytical-oncology/volume-4-number-3/89-abstract/jao/1769-abstract-erlotinib-as-second-line-therapy-for-patients-with-advanced-non-small-cell-lung-cancer-and-wild-type-egfr-tumors
Enlace

Areizaga LM, Carrasco JA, de las Peñas R, Sala MÁ. Tumores mesenquimales de comportamiento localmente agresivo. In: Martín Brogo J, Valverde C, Cubedo R, Cruz J (eds.). Tratado de sarcomas de partes blandas. Madrid: NPG editorial; 2015. ISBN: 978-84-940238-4-2. http://www.mcu.es/webISBN/tituloDetalle.do?sidTitul=2189870&action=busquedaInicial&noValidating=true&POS=0&MAX=50&TOTAL=0&prev_layout=busquedaisbn&layout=busquedaisbn&language=es
Enlace

León L, Antón-Aparicio LM, Esteban-González E, Lázaro-Quintela M, Vázquez-Estévez S. Side Effects of Targeted Therapy. In: Bukowski RM, Figlin RA (eds.). Renal Cell Carcinoma: Molecular Targets and Clinical Applications. Springer New York; 2015. p. 377–416. ISBN: 9781493916221; 9781493916214. https://www.scopus.com/inward/record.uri?eid=2-s2.0-84944617211&doi=10.1007%2F978-1-4939-1622-1&partnerID=40&md5=bf8e2dbe634de533fe761b000ee5ba2d
Enlace

Vázquez ML, Gallardo Martín E, Pena C, Lorenzo I, Constenla M. Capítulo 38. Cáncer Colorrectal no Polipósico. In: Pazos A, Ulla J (eds.). Abordaje multidisciplinar de cáncer colorrectal. 1st ed. Santiago de Compostela: Andavira Editora S.L.; 2015. p. 611–32. ISBN: 978-84-8408-795-3. http://www.andavira.com/ebooks/cancer_colorrectal/files/assets/basic-html/page-16.html#
Enlace

Casal Rubio J, Fírvida-Pérez JL, Lázaro-Quintela M, Barón-Duarte FJ, Alonso-Jáudenes G, Santomé L, Afonso-Afonso FJ, Amenedo M, Huidobro G, Campos-Balea B, López-Vázquez MD, Vázquez S. A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study. Cancer Chemother Pharmacol. 2014 Mar;73(3):451–7. PMID: 24352251. DOI: 10.1007/s00280-013-2370-z. IF2014: 2.769; Q3. http://www.ncbi.nlm.nih.gov/pubmed/24352251
Enlace

Fernández O, Afonso J, Vázquez S, Campos B, Lázaro M, León L, Antón Aparicio LM. Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel. Anticancer Drugs. 2014 Mar;25(3):237–43. PMID: 24217332. DOI: 10.1097/CAD.0000000000000045. IF: 1.784; Q4. http://www.ncbi.nlm.nih.gov/pubmed/24217332
Enlace

Juan O, Sánchez-Hernández A, Vázquez S, Casal J, Firvida JL, Aparisi F, Muñoz J, García-Sánchez J, Gironés R, Lázaro M, Giner V. Full-dose cisplatin and oral vinorelbine concomitant with radiotherapy in unresectable stage III non-small cell lung cancer: a multi-center phase II study. Anticancer Res. 2014 Apr;34(4):1959–66. PMID: 24692732. IF: 1.826; Q4. http://www.ncbi.nlm.nih.gov/pubmed/24692732
Enlace

Santos M, Martínez-Fernández M, Dueñas M, García-Escudero R, Alfaya B, Villacampa F, Saiz-Ladera C, Costa C, Oteo M, Duarte J, Martínez V, Gómez-Rodriguez MJ, Martín ML, Fernández M, Viatour P, Morcillo MA, Sage J, Castellano D, Rodriguez-Peralto JL, de la Rosa F, Paramio JM. In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancer. Cancer Res. 2014 Nov;74(22):6565–77. PMID: 25252918. DOI: 10.1158/0008-5472.CAN-14-1218. http://www.ncbi.nlm.nih.gov/pubmed/25252918
Enlace

Vazquez S, Lazaro M, Luis Firvida J. Second-line treatment in advanced non-small-cell lung cancer in the epidermal growth factor receptor wild-type population: review of patient profile. Anticancer Drugs. 2014 Apr;25(4):368–74. PMID: 24384805. DOI: 10.1097/CAD.0000000000000066. IF: 1.784; Q4. http://apps.isiknowledge.com/full_record.do?product=UA&search_mode=GeneralSearch&qid=4&SID=S2uGjT3vB4ldo5YTNQB&page=1&doc=7
Enlace